

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

09/29/98



jc-598 U.S. PTO

Attorney Docket No.: 4102-1


Inventors: Ian F. C. McKenzie of Brunswick, Australia  
Vasso Apostolopoulos of St. Albans, Australia  
Geoffrey A. Pietersz of Greensborough, Australia

Express Mail Label No.: EM552805237US

Title: COMPOSITION FOR IMMUNOTHERAPY AND USES THEREOF

jc-523 U.S. PTO

09/16/98



09/29/98

Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

The present application is a continuation-in-part of U.S. Patent Application Serial No. 08/833,807, filed April 9, 1997, which is a continuation of U.S. Patent Application Serial No. 08/340,711, filed November 16, 1994. Both U.S. Patent Application Serial No. 08/833,807 and 08/340,711 are incorporated herein by this reference in their entirety. The present application also claims priority from U.S. Provisional Application Serial No. 60/060,594, filed September 29, 1997, incorporated herein by reference in its entirety.

Enclosed for filing with the above-identified utility patent application are the following:

1. Specification (Total Pages of Text, including Abstract and Claims: 93)
2. Drawing(s) (35 USC 113) (Total Sheets: 14) ☐ FORMAL ☒ INFORMAL
3. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
  - a. Computer Readable Copy
  - b. Paper Copy (identical to computer copy)
  - c. Attorney for applicants hereby asserts pursuant to 37 CFR § 1.821(f) that the content of the paper and computer readable copies of SEQ ID No:1 through SEQ ID No:9 submitted herewith are identical
4. Return Postcard (MPEP 503) (should be specifically itemized)

## FEE CALCULATION:

	(COL. 1) NO. FILED			(COL. 2*) NO. EXTRA	SMALL ENTITY			LARGE ENTITY	
					RATE	FEE		RATE	FEE
BASIC FEE:						\$395.00	OR		\$790.00
TOTAL CLAIMS	69	-	20	49	X \$11 =	\$539.00	OR	X \$22 =	
INDEP. CLAIMS:	9	-	3	6	X \$41 =	\$246.00	OR	X \$82 =	
MULTIPLE DEPENDENT CLAIMS					+ \$135 =	\$	OR	+\$270 =	
*IF THE DIFFERENCE IN COL. 2 IS LESS THAN ZERO, ENTER "0" IN COL. 2.					TOTAL:	\$0.00			

## OTHER INFORMATION:

1. **NO FEE IS ENCLOSED**
2. Correspondence Address:

Gary J. Connell  
SHERIDAN ROSS P.C.  
1700 Lincoln Street, Suite 3500  
Denver, Colorado 80203  
Telephone: (303) 863-9700  
Facsimile: (303) 863-0223

Respectfully Submitted,

SHERIDAN ROSS P.C.

Gary J. Connell  
Registration No. 32,020

Date: September 29, 1998

## COMPOSITIONS FOR IMMUNOTHERAPY AND USES THEREOF

## CROSS-REFERENCE TO RELATED APPLICATIONS

5 The present application is a continuation-in-part of U.S.  
Patent Application Serial No. 08/833,807, filed April 9, 1997,  
for "Antigen Carbohydrate Compounds and Their Use in  
Immunotherapy", which is a continuation of U.S. Patent  
Application Serial No. 08/340,711 for "Antigen Carbohydrate  
Compounds and Their Use in Immunotherapy", filed November 16,  
10 1994. Both U.S. Patent Application Serial No. 08/833,807 and  
08/340,711 are incorporated herein by this reference in their  
entirety. The present application also claims priority from  
U.S. Provisional Application Serial No. 60/060,594, filed  
September 29, 1997, for "Compositions for Immunotherapy and  
15 Uses Thereof", incorporated herein by reference in its  
entirety.

## FIELD OF THE INVENTION

20 The present invention relates to a product and process  
for regulating the activity of T cells using a carbohydrate  
compound. The product of the present invention particularly  
concerns a mannose receptor-bearing cell and an oxidized  
mannose linked to an antigen, the product being capable of  
enhancing MHC class I antigen presentation.

## BACKGROUND OF THE INVENTION

Cancer is a major cause of death and severe trauma in modern society. Cancer afflicts the young, old, males, females and peoples of all races may contract cancer, although cancer in children is relatively rare, perhaps with the exception of childhood leukemia. In western society, cancer of the colon and lung cancer are major diseases. In women, breast cancer is the most common form of cancer.

Many cancers are accompanied by overproduction of human mucin. Mucins are heavily glycosylated proteins (greater than about 100 kilodalton (kD) which are produced by many epithelial cells and tumors (Gendler et al., *J. Biol. Chem.*, 263:12820-12823, 1988). Mucins found on cancer cells are different in some respects to those on normal epithelial cells, in that some mucins have a deficiency in their carbohydrate coat which leaves the protein core exposed (Harisch et al., *J. Biol. Chem.*, 264:872-883, 1989). There are seven forms of known human mucin designated MUC1, MUC2, MUC3, MUC4, MUC5, MUC6 and MUC7 (Marjoliijn et al., *J. Biol. Chem.*, 265:5573-5578, 1990; Crocker et al., *Br. J. Cancer*, 55:651-652, 1987; Apostolopoulos et al., *Crit. Rev. Immunol.*, 14:293-309, 1994; and Bobek et al., *J. Biol. Chem.*, 268:20563-20569, 1993). MUC1 is the most ubiquitous. The various mucins

all have very similar properties, that is, they are transmembrane glycoproteins, all having a variable number of repeated amino acid sequences, which have a high content of serine, threonine and proline. Overproduction of aberrantly glycosylated mucins (either non-glycosylated or a deficiency in glycosylation) is characteristic of tumors of the breast, ovary, pancreas, colon, lungs, prostate and other tumors of secretory tissue. The copy DNA (cDNA) sequences of the respective protein cores of the human mucins MUC1 to MUC7 have been cloned and characterized and have been found to contain highly repetitive central portions of varying numbers of repeats of particularly amino acid motifs (known as VNTR's). By way of example, MUC1 consists of unique amino and carboxyl terminal sequences separated by a highly repetitive central portion containing forty to eighty tandemly arranged copies or repeats of a twenty amino acid motif. The VNTR's of MUC1 through MUC7 are set forth below:

MUC1 VNTR- SAPDTRPAPGSTAPPAHGV (SEQ ID NO:1)

MUC2 VNTR- PTTTPISTTTMVTPTPTGTQT (SEQ ID NO:2)

MUC3 VNTR- HSTPSFTSSITTTETTS (SEQ ID NO:3)

MUC4 VNTR - TSSASTGHATPLPVT (SEQ ID NO:4)

MUC5 VNTR - PTTSTTSA (494 base pair insert - eight amino acid tandem repeat)

MUC6 VNTR - 169 amino acid repeat unit (SEQ ID NO:5)

MUC7 VNTR- TTAAPPTPPATTTPAPPSSSAPPE (SEQ ID NO:6)

5 The repeated subunit of MUC6 comprises 169 amino acids, although at this time the amino acid sequence of this repeat unit has not been fully characterized. The MUC7 sequence has recently been published (Bobek et al., *ibid.*).

10 Finn and colleagues have demonstrated that in the lymph nodes of patients with breast cancer (Barnd et al., *Proc. Natl. Acad. Sci USA*, 86:7159-7163, 1989; and Jerome et al., in *Cell. Immunity and Immunotherapy of Cancer*, pp. 321-328, 1990), cancer of the pancreas, ovary and other tumors, cytotoxic lymphocytes are present which react with human mucin. Antibodies to the MUC1 peptide can block the activity of these cytotoxic T lymphocytes on MUC1 and target cells  
15 (Barnd et al., *ibid.*; and Jerome et al., *ibid.*). Recently, cytotoxic lymphocytes to a murine lung cancer have also been described (Mandelboimo et al., *Nature*, 369:67-71, 1994).

20 The surgery associated with tumor removal is traumatic to the patient, often disfiguring, and costly. Established chemotherapeutic and radiation procedures for tumor treatment which may be carried out in place of, or in conjunction with, surgical procedures are often debilitating and associated with severe side-effects. There is accordingly an urgent need for

immunoregulatory compositions and methods for the prevention/  
treatment of tumors.

There is an urgent need for new compositions and methods  
for the treatment of cancer. Similarly, there is a pressing  
5 need for alternative compositions and methods for the  
treatment of other disease states such as type I allergies,  
malaria, HIV, dental caries, flu, cholera, foot and mouth  
disease, meningitis, Leishmania infection, whooping cough,  
rabies, Streptococcus infection, respiratory infection,  
10 measles, Lyme disease, tuberculosis, bacterial meningitis,  
shingles, rubella, hepatitis, herpes, hepatitis A, polio,  
venereal disease/trachoma, hepatitis B, common cold, cervical  
cancer, meningitis/pneumonitis, chicken pox, small pox and  
pneumonia/PUO.

#### 15 SUMMARY OF THE INVENTION

The present invention provides an immunoregulatory  
composition that is capable of regulating a T lymphocyte (T  
cell) response in an animal, thereby treating or alleviating  
the occurrence of disease. The present invention is  
20 advantageous because it regulates T cell responses by  
delivering an antigen to the MHC class I pathway for  
presentation by class I molecules, thereby inducing cytotoxic  
T lymphocytes and T1 (i.e., TH1) cytokine production, e.g.,

IL-2, IL-12 and gamma interferon. The invention is particularly advantageous in that it regulates T cell responses by increasing the uptake of an antigen:carbohydrate polymer conjugate of the present invention by inducing  
5 receptors for mannose on cells capable of stimulating T cells reactive to the antigen of the conjugate. In addition, the invention is particularly advantageous in that it enables an antigen, for example a mucin:carbohydrate polymer conjugate of the present invention, to be administered to an animal in such  
10 a manner that binding of the antigen, e.g., mucin, by naturally occurring antibodies directed against or cross-reactive with the antigen in the animal is avoided. Moreover, an immunoregulatory composition of the present invention possesses the advantage of being substantially non-toxic upon  
15 administration to animals, and as a consequence the compositions are well tolerated by animals.

One embodiment of the present invention includes an immunoregulatory composition comprising isolated mannose receptor-bearing cells and a conjugate comprising an antigen  
20 and mannose including fully oxidized mannose and/or partially reduced mannose having aldehydes. Preferred antigens include tumor, viral, fungal, protozoal or bacterial antigens.

Preferred oxidized mannose comprises a carbohydrate polymer with aldehydes.

Another embodiment of the present invention includes a composition comprising an immunoregulatory mannose receptor-bearing cell population, the population can be derived by culturing mannose receptor-bearing cells under conditions effective to produce the immunoregulatory mannose receptor-bearing cell population, the conditions comprising an antigen delivery medium. A preferred antigen delivery medium comprises a conjugate comprising an antigen and mannose including oxidized mannose and/or partially reduced mannose having aldehydes.

Yet another embodiment of the present invention includes an immunoregulatory mannose receptor-bearing cell population, in which the immunoregulatory mannose receptor-bearing cell population can be derived by a method comprising: (a) culturing mannose receptor-bearing cells *in vitro* with one or more biological response modifiers to produce an enhanced mannose receptor-bearing cell population; and (b) incubating the enhanced mannose receptor-bearing cell population with a conjugate comprising an antigen and mannose including oxidized mannose and/or partially reduced mannose having aldehydes, to obtain the immunoregulatory mannose receptor-bearing cell



population. Preferred biological response modifiers include cytokines and vitamins.

5 The present invention also includes an antigen delivery vehicle, comprising an isolated mannose receptor-bearing cell and a conjugate comprising antigen and a carbohydrate polymer comprising mannose including fully oxidized mannose and/or partially reduced mannose having aldehydes. Preferred antigen includes mucin.

10 The present invention also includes a method for obtaining a population comprising immunoregulatory mannose receptor-bearing cells, the method comprising culturing a population of cells enriched for mannose receptor-bearing cells under conditions effective to obtain immunoregulatory mannose receptor-bearing cells, the conditions comprising an  
15 antigen delivery medium. Preferably, the method includes incubating the population of cells enriched for mannose receptor-bearing cells in the presence of one or more biological response modifier prior to the step of culturing.

20 Another embodiment of the present invention includes a method to induce an immune response comprising administering to a recipient animal an effective amount of an immunoregulatory composition comprising mannose receptor-bearing cells and a conjugate comprising an antigen and

mannose including fully oxidized mannose and/or partially reduced mannose having aldehydes.

5 The invention also includes a method to induce an immune response to an antigen, comprising contacting an isolated mannose receptor-bearing cell with a conjugate comprising antigen and mannose including fully oxidized mannose and/or partially reduced mannose having aldehydes, and administering the contacted cell to an animal.

10 Also included in the present invention is a method for delivering an antigen to an animal by administering to an animal a mannose receptor-bearing cell that has been contacted with a conjugate comprising an antigen and mannose including fully oxidized mannose and/or partially reduced mannose having aldehydes, in which the mannose receptor-bearing cell is  
15 capable of presenting the antigen to a T cell in such a manner that a response is elicited from the T cell.

20 Yet another embodiment of the present invention is a compound comprising an antigen conjugated to a carbohydrate polymer comprising partially reduced carbohydrate having aldehyde groups.

#### BRIEF DESCRIPTION OF THE FIGURES

Fig. 1 illustrates CTLp frequencies obtained by a single *in vitro* immunization compared to three *in vivo* immunizations

using peritoneal exudate cells pulsed with different forms of mannose polymer.

Fig. 2 illustrates the minimum number of antigen presenting mannose receptor-bearing cells needed to induce a T cell response.

Fig. 3 illustrates tumor growth in mice immunized with peritoneal exudate antigen presenting mannose receptor-bearing cells pulsed with oxidized MUC1, oxidized mannan fusion protein or buffer alone.

Fig. 4 illustrates CTLp frequencies using peritoneal exudate cells, containing antigen presenting mannose receptor-bearing cells, treated with GM-CSF or interferon gamma and pulsed with oxidized mannan fusion protein.

Fig. 5 illustrates CTLp frequencies of GM-CSF or G-CSF knockout mice immunized with oxidized mannan fusion protein.

Fig. 6 illustrates CTLp frequencies in mice injected with GM-CSF prior to injection with oxidized mannan fusion protein.

Fig. 7 illustrates CTLp frequencies in semi-allogeneic and allogenic recipients of macrophages pulsed with oxidized mannan fusion protein.

Fig. 8 illustrates FACS analysis of the cross reaction between MUC1 and gal on Gala(1,3)Gal- cell lines and Gala(1,3)Gal+ cell lines.

Fig. 9 illustrates the detection of anti-MUC1 peptide antibodies in serum isolated from Gal o/o mice and C57BL/6 mice immunized with oxidized mannan fusion protein.

5 Fig. 10 illustrates the detection of anti-MUC1 peptide antibodies in serum isolated from Gal o/o mice immunized with either oxidized mannan fusion protein or macrophages pulsed with oxidized mannan fusion protein.

10 Fig. 11 illustrates the difference in CTLp frequencies between normal mice injected with ox-M-FP and ox-M-FP mixed with gal o/o serum.

Fig. 12 illustrates the difference in CTLp frequencies between mice immunized with macrophage cells pulsed with ox-M-SIINFEKL and mice immunized with macrophage cells pulsed with ox-M-SIINFEKL mixed with gal o/o serum.

15 Fig. 13 illustrates the difference in CTLp frequencies between normal and Gal o/o mice immunized with macrophages and oxidized mannan fusion protein in the presence of either normal mouse serum or serum isolated from Gal o/o mice.

20 Fig. 14 illustrates coupling of MUC1 fusion protein to mannan.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a product and process for treating or alleviating the occurrence of disease in an animal

susceptible to immunoregulation. In particular, the product includes an immunoregulatory composition comprising carbohydrate receptor-bearing cells, and a conjugate comprising an antigen and oxidized carbohydrate.

5 One embodiment of the present invention is an immunoregulatory composition comprising isolated carbohydrate receptor-bearing cells and a conjugate comprising an antigen and oxidized carbohydrate. As used herein, the term "oxidized carbohydrate" can refer to a completely (i.e., fully) oxidized carbohydrate or a partially reduced carbohydrate having aldehydes (described in detail below). Another embodiment of the present invention is receptor-bearing cells contacted with a conjugate comprising an antigen and oxidized carbohydrate. According to the present invention, reference to a composition comprising "carbohydrate receptor-bearing cells and a conjugate comprising an antigen and oxidized carbohydrate" or "carbohydrate receptor-bearing cells contacted with a conjugate comprising an antigen and oxidized carbohydrate" can encompass one or more of: (1) a mixture of conjugate and receptor-bearing cells wherein the conjugate is not bound to the cells; (2) a mixture of conjugate and receptor-bearing cells wherein the conjugate is bound to the cells, but not yet internalized; (3) receptor-bearing cells wherein the conjugate

has been internalized; (4) receptor-bearing cells wherein the conjugate has been internalized and processed; and/or (5) receptor-bearing cells wherein the conjugate has been internalized, processed and presented. It is to be noted that the term "a" or "an" entity refers to one or more of that entity; for example, a compound refers to one or more compounds. As such, the terms "a" (or "an"), "one or more" and "at least one" can be used interchangeably herein. The term "isolated" refers to an entity, such as a cell, polypeptide or peptide, that has been removed from its natural milieu. As such, "isolated" does not reflect the extent to which the entity has been purified. As used herein, a "carbohydrate receptor-bearing cell" refers to any type of cell that contains a receptor (i.e., protein) that specifically binds to carbohydrate on the surface of the cell or that is capable of expressing a carbohydrate receptor. Carbohydrate receptors as used herein refer to those carbohydrate receptors known to those of skill in the art. It is to be noted that carbohydrate receptor-bearing cells can be part of a population of cells containing varying concentrations of carbohydrate receptor-bearing cells. Thus, a population of carbohydrate receptor-bearing cells includes a population of cells that includes at least one carbohydrate

receptor-bearing cell. Alternatively, a population of carbohydrate receptor-bearing cells can comprise a pure population of carbohydrate receptor-bearing cells (i.e., 100% carbohydrate receptor-bearing cells). Preferably, a

5 population of carbohydrate receptor-bearing cells comprises at least about 25%, more preferably at least about 50%, more preferably at least about 75%, even more preferably at least about 80%, even more preferably at least about 85%, even more preferably at least about 90% and even more preferably at least about 95% carbohydrate receptor-bearing cells. It is

10 within the knowledge of one of skill in the art to note that the relative purity of a population of carbohydrate receptor-bearing cells can be dependent upon the source of the carbohydrate receptor-bearing cells. As used herein, an

15 "enriched population of carbohydrate receptor-bearing cells" refers to a population of cells that has been treated in such a manner that non-carbohydrate receptor-bearing cells (i.e., cells having, or being capable of expressing, carbohydrate receptor) have been removed from the population. As used

20 herein, an "enhanced carbohydrate receptor-bearing cell population" refers to a population of cells that has been treated in such a manner that the number of cells bearing carbohydrate receptor, and/or the number of carbohydrate

receptors on a cell, increases compared with cells in the population prior to the treatment. Carbohydrate receptor-bearing cells can be enriched in a population of cells from, for example, blood, bone marrow, lymph node or bronchial lavage, using methods standard in the art, including, but not limited to, panning, leukophoresis or growth enriching techniques. Methods to enhance a population of carbohydrate receptor-bearing cells are described in detail herein.

Suitable carbohydrate receptor-bearing cells for use with the present invention include cells that have been isolated from an animal or cells that have been adapted to tissue culture and are grown *in vitro*. As used herein, the term "*in vitro*" refers to methods performed outside of an animal. The term "*ex vivo*" refers to methods performed on a portion (e.g., tissue, cells and fluids) of an animal (i.e., donor animal), outside of the animal, with the intent to return the portion to an animal (i.e., recipient animal). The recipient animal need not be the same animal as the donor animal. Preferred carbohydrate receptor-bearing cells of the present invention are derived from bone marrow, peripheral blood leukocytes, alveolar lung macrophages, stem cells, tumor cells and/or stromal cells. Cells can be isolated from an animal using standard methods known in the art depending upon the source of



the cells. More preferred carbohydrate receptor-bearing cells include cells that are enriched for antigen presenting cells (APC). Suitable antigen presenting cells include cells capable of presenting an antigen to a T cell, thereby eliciting a T cell response. A portion of an immune response is regulated by presentation of antigen by major histocompatibility complexes (MHCs). MHCs bind to peptide fragments derived from antigens to form complexes that are recognized by T cell receptors on the surface of T cells, giving rise to the phenomenon of MHC-restricted T cell recognition. A "T cell response" refers to the reaction of a T cell to antigen presented by the MHC and peptide complex. A response by T cell can include activation of the T cell such as with a naive T cell, or stimulation of a T cell such as with a T cell that is already activated. A "cell mediated immune response" refers to an immune response that involves the activation and/or stimulation of a T cell. According to the present invention, a conjugate or composition of the present invention can elicit a T cell response by activating and/or stimulating T cells, in particular antigen-specific T cells. Preferred antigen presenting cells include dendritic cells, macrophages, monocytes and B lymphocytes (B cells), with macrophage and monocyte cells being more preferred. Even

more preferred carbohydrate receptor-bearing cells include mannose receptor-bearing cells, i.e. cells having mannose receptors. As used herein, "receptor-bearing" and receptor positive cells are intended to be used interchangeably. Even more preferred carbohydrate receptor-bearing cells of the present invention include cells that are enriched for cells that bind specifically to an antibody including F4/80, anti-MAC-1 antibody, anti-mannose receptor antibody, NLDC-145, anti-CD14 antibody, anti-CD11b antibody, anti-CD11c antibody, anti-CD68 antibody, anti-CD80 antibody or anti-CD86 antibody.

Preferably, a carbohydrate receptor-bearing cell of the present invention originates from an animal that is the intended recipient of the immunoregulatory composition or an animal that is MHC matched to the intended recipient, such as from an unrelated donor or a relative of the animal, preferably a sibling of an animal. A preferred carbohydrate receptor-bearing cell is obtained from an animal that is the intended recipient of the immunoregulatory composition of the present invention.

In one embodiment, carbohydrate receptor-bearing cells of the present invention include carbohydrate receptor-bearing cells that have been contacted with a compound capable of inducing the expression of receptors for carbohydrate on cells

capable of expressing carbohydrate receptors. Suitable compounds useful for inducing the expression of carbohydrate receptors include biological response modifiers, such as cytokines. Preferred biological response modifiers of the present invention include any compound capable of inducing the expression of carbohydrate receptors on monocytes, macrophages and/or dendritic cells. More preferred biological response modifiers include, but are not limited to, cytokines and vitamins. Preferred cytokines useful for increasing the number of carbohydrate receptors on the surface of a cell include, but are not limited to, granulocyte macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3), interleukin-4 (IL-4), interferon gamma, Flt-3 ligand; granulocyte colony stimulating factor (G-CSF); interleukin-12 (IL-12), tumor necrosis factor alpha (TNF- $\alpha$ ), macrophage colony stimulating factor (M-CSF), interleukin-3 (IL-3), interleukin-4 (IL-4) and/or interleukin-6 (IL-6), with GM-CSF and IL-3 being more preferred. A preferred vitamin for use with the present invention includes, but is not limited to, vitamin D.

According to the present invention, carbohydrate receptor-bearing cells can be contacted with a biological response modifier prior to or after the carbohydrate receptor-

bearing cells are removed from an animal. As such, a biological response modifier can be administered to an animal under conditions suitable for inducing carbohydrate receptors on cells *in vivo*.

5 In a preferred embodiment, carbohydrate receptor-bearing cells of the present invention include a population of cells containing monocytes, macrophages and/or dendritic cells that have been contacted with a formulation comprising GM-CSF, IL-3, IL-4, TNF gamma and/or vitamin D.

10 One embodiment of the present invention is a method for obtaining a cell population comprising immunoregulatory carbohydrate receptor-bearing cells, the method comprising culturing a population of cells enriched for carbohydrate receptor-bearing cells under conditions effective to obtain  
15 immunoregulatory carbohydrate receptor-bearing cells, in which the conditions comprise an antigen delivery medium. An antigen delivery medium includes a conjugate of the present invention, preferably a conjugate comprising an antigen and oxidized carbohydrate. Additional components of an antigen  
20 delivery medium include suitable cell culture medium such as that disclosed herein in the Examples and those known to one of skill in the art. Methods to culture a population of cells enriched for carbohydrate receptor-bearing cells are disclosed

herein in the Examples. Preferably, the culturing step is performed from about 1 day to about 12 days, more preferably from about 3 days to about 10 days, and even more preferably from about 5 days to about 7 days, with 5 days being even more preferred.

The present invention also includes an immunoregulatory carbohydrate receptor-bearing cell population that can be derived by the method comprising: (a) culturing carbohydrate receptor-bearing cells *in vitro* with one or more biological response modifiers to produce an enhanced carbohydrate receptor-bearing cell population; and (b) incubating the enhanced carbohydrate receptor-bearing cell population with a conjugate comprising an antigen and oxidized carbohydrate to obtain an immunoregulatory carbohydrate receptor-bearing cell population. Preferably, the step of culturing is performed from about 1 hour to about 6 hours, more preferably from about 2 hours to about 4 hours and even more preferably for about 3 hours. A preferred carbohydrate receptor-bearing cell population derived by the present method include mannose receptor-bearing cells.

According to the present invention, an antigen includes a polypeptide or a peptide. Antigens of the present invention initiates a series of events culminating in an immune

response, cellular or humoral. In particular, antigens of the present invention include those that are presented to T cells in the context of MHC. Suitable antigens for use with the present invention include polypeptides and peptides.

5 Polypeptides comprising an antigen may be produced according to well known procedures such as peptide synthesis, protein purification, or expression of polypeptides in host cells. Peptide synthesis may be employed for polypeptides containing up to about a hundred amino acids (for example, five repeated subunits of MUC1). Generally, for polypeptide containing  
10 about twenty or more amino acids, the preferred means of production is recombinant expression in a host cell, preferably a prokaryotic host cell, and more preferably a bacterial host cell. However, as discussed earlier, eukaryotic systems may also be used. Procedures for expression of  
15 recombinant proteins in host cells are well established, see, for example, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring Harbor, 1989.

According to the present invention, a peptide of the  
20 present invention is an isolated peptide. An isolated peptide refers to a peptide that is not in its natural milieu. An isolated peptide of the present invention can be obtained from its natural source, produced by proteolysis of a full-length

protein or larger protein fragment, produced using recombinant DNA technology or synthesized using standard chemical peptide synthesis methods.

Insofar as the present invention is concerned, the antigen can be an autoantigen or an antigenic peptide derived from a virus, microorganism or plant or an amino acid subunit of at least five amino acids in length of an autoantigen or an antigenic peptide derived from a virus, microorganism or plant. The antigen of the present invention can also consist of more than one, five or more amino acid subunits (as mentioned above) linked together. These linked subunits may be from the same or different origins within the bounds described above. An antigenic peptide of the present invention is capable of binding to an MHC molecule.

Examples of the antigens suitable for use in a composition of the present invention include: tumor antigens including, but not limited to CEA, p53, Her2/neu, Erb2, melan A, MAGE antigens, nm23, BRACA1, BRACA2; pollens, hepatitis C virus (HIV) core, E1, E2 and NS2 proteins; Plasmodium falciparum circumsporozoite protein; HIV-gp120/160 envelope glycoprotein; streptococcus surface protein Ag; influenza nucleoprotein; hemagglutinin- neuraminidase surface infection; TcpA pilin subunit; VP1 protein; LMCV nucleoprotein;

Leishmania major surface glycoprotein (gp63); Bordetella  
 pertussis surface protein; rabies virus G protein;  
 Streptococcus M protein; respiratory syncytial virus (RSV) F  
 or G proteins; Epstein Barr virus (EBV) gp340 or nucleantigen  
 5 3A, hemagglutinin, Borrelia burgdorferi outer surface protein  
 (Osp) A, Mycobacterium tuberculosis 38 kDa lipoprotein or  
 Ag85, Neisseria meningitides class 1 outer protein, Varicella  
 zoster virus IE62 and gpI, Rubella virus capsid protein,  
 Hepatitis B virus pre S1 ag, Herpes simplex virus type I  
 10 glycoprotein G or gp D or CP27, Murray valley encephalitis  
 virus E glycoprotein, Hepatitis A virus VP1, polio virus  
 capsid protein VP1, VP2 and VP3, chlamydia trachomatis surface  
 protein, Hepatitis B virus envelope Ag pre S2, Human  
 rhinovirus (HRV) capsid, papillomavirus peptides from oncogene  
 15 E6 and E7, Listeria surface protein, Varicella virus envelope  
 protein, Vaccinia virus envelope protein, Brucella surface  
 protein, a combination of one or more of said antigens, an  
 amino acid subunit of said antigens comprising five or more  
 amino acids in length or combinations of one or more of such  
 20 subunits.

The antigens of the present invention can also consist of  
 whole cells or sub-cellular fractions thereof. Such cells or  
 sub-cellular fractions thereof may be derived from any tumor



type or other source. Examples of cancer types from which the whole cells or sub-cellular fractions may be derived are breast, lung, pancreas and colon cancer and melanoma. Some further examples of specific antigens obtained from tumors are  
5 melanoma specific antigen (for example, the MAGE series antigen), carcino embryonic antigen (CEA) from colon and other cancers or indeed antigens extracted from any tumor.

10 This invention includes any one or more of the antigens listed above, and in particular includes any one or more of the human mucins MUC1 through MUC7 which, as mentioned above, all comprise highly repetitive central portions of repeated amino acid sequences which are high in serine, threonine and proline. In particular, the compositions of this invention may comprise a human mucin polypeptide (containing a variable  
15 number of repeats associated with normal allelic variation), or may comprise one or more of the repeated sequences of human mucin, preferably two to eighty, more preferably two to twenty and even more preferably two to ten repeated subunits of human mucin. The human mucin and subunits thereof are preferably  
20 non-glycosylated or aberrantly glycosylated so as to provoke an immune response to the mucins found on cancer cells which have a deficiency in their carbohydrate coat which leaves the protein core exposed. The use of human mucin MUC1 is

particularly preferred although it is to be clearly understood that the invention extends to the use of any antigen and especially to the use of the human mucins MUC1 through MUC7. For the purpose of convenience, the term MUC will hereafter be used to refer to any of the human mucins MUC1 through MUC7 and repeated subunits thereof. While only the human mucins will be dealt with hereafter, it must be kept in mind that this invention equally relates to any other antigen as mentioned previously.

10           Fragments of MUC may also be conjugated to a carbohydrate polymer. These fragments can comprise any portion of a molecule MUC that is capable of being conjugated to a carbohydrate. Fragments of a MUC molecule include fragments of the naturally-occurring sequence of a MUC molecule and/or  
15           a sequence derived from a MUC molecule but modified to improve binding of a MUC molecule to a MHC class I molecule. Methods to mimic a MUC molecules include methods known to those in the art, such as peptide synthesis or recombinant DNA techniques. Preferred fragments of a MUC molecule comprise peptides of a  
20           MUC molecule. A preferred peptide of a MUC molecule is from about five to about twenty amino acids. Preferred fragments of a MUC molecule comprise non-VNTR or VNTR regions. More preferred fragments of a MUC molecule include peptides having

an amino acid sequence including APDTR (SEQ ID NO:7),  
APDTRPAPG (SEQ ID NO:8), DTRPAPGSTAPP (SEQ ID NO:9), and the  
like. For convenience of description these fragments are also  
included with the definition MUC. Similarly, other antigen  
5 fragments comprising at least five amino acids may be  
conjugated to a carbohydrate polymer.

A specified antigen of the present invention may form  
part of a fusion protein in order to facilitate expression and  
purification on production of the fusion protein in  
10 recombinant host cells. The non-antigen portion of the fusion  
protein would generally represent the N-terminal region of the  
fusion polypeptide with the carboxy terminal sequences  
comprising antigen sequences. Fusion proteins may be selected  
from glutathione-S-transferase,  $\beta$ -galactosidase, or any other  
15 protein or part thereof, particularly those which enable  
affinity purification utilizing the binding or other affinity  
characteristics of the protein to purify the resultant fusion  
protein. The protein may also be fused to the C-terminal or N-  
terminal of the carrier protein. The nature of the fusion  
20 protein will depend upon the vector system in which fusion  
proteins are produced. An example of a bacterial expression  
vector is pGEX which on subcloning on a gene of interest into  
this vector produces a fusion protein consisting of

glutathione-S-transferase with the protein of interest. Examples of other vector systems which give rise to fusion proteins with a protein of interest are described in Sambrook et al., *ibid.*, which is incorporated herein in its entirety by reference. These can be included or cleaved; if included they could have a "carrier" function.

The protein or fusion protein may be expressed in a number of prokaryotic (*E. coli* or *B-subtilis*) or eukaryotic (baculovirus, CHO cells, Cos cells or yeast) expression systems. In some of these systems, for example, baculovirus or yeast, by introducing glycosylation motifs into the protein or fusion protein, the mannose rich glycosylation may be adequate; negating the need for chemically linking with mannose rich carbohydrate polymers. These novel fusion proteins may be used with or without mild periodate oxidation.

In one embodiment, an antigen of the present invention is conjugated to a carbohydrate polymer. The number of repeated monomer units in the carbohydrate polymer is not important but generally carbohydrate polymers would comprise at least twenty monomer units, preferably in excess of one hundred monomer units, more preferably in excess of one thousand monomer units, and still more preferably in excess of ten thousand monomer units or more. Carbohydrate polymers may be a mixture

of polysaccharide chains of varying molecular weights. The carbohydrate portion of a composition of the present invention can comprise any carbohydrate polymer, for example, polymers including glucose, galactose, mannose, xylose, arabinose, fucose, glucosamine, galactosamine, rhamnose, 6-0-methyl-D-galactose, 2-0-acetyl- $\beta$ -D-xylose, N-acetyl-glucosamine, iduronate, gluuronate, mannuronate, methyl galacturonate, a -D-galactopyranose-6-sulphate, fructose and  $\alpha$ -abequose, conformation and configuration isomers thereof, or a carbohydrate formed of two or more different monomer units. A preferred carbohydrate polymer of the present invention comprises mannose. A more preferred carbohydrate polymer is a polymer of the carbohydrate mannose. An even more preferred carbohydrate polymer is a polymer of fully oxidized mannose and/or partially reduced mannose having aldehydes.

A preferred carbohydrate comprises an oxidized carbohydrate treated in such a manner that the carbohydrate is partially reduced. A more preferred carbohydrate comprises an oxidized carbohydrate treated in such a manner that aldehyde groups of the carbohydrate are substantially not reduced, and predominantly Schiff's bases are reduced. A suitable reagent for partially reducing a carbohydrate according to the present invention includes, but is not limited to, sodium

cyanoborohydride. It is understood that other reagents suitable for partially reducing a carbohydrate according to the present invention will be apparent to those of skill in the art and are intended to be encompassed herein. Treatment of an oxidized carbohydrate with sodium cyanoborohydride, for example, retains aldehyde groups while reducing other groups, such as Schiff's bases. Without being bound by theory, the present inventors believe that exposed and/or free aldehyde groups of an oxidized carbohydrate according to the present invention are important for delivery of the carbohydrate and antigen conjugate of the present invention, possibly by altering uptake, release, or leakage of antigen from the endosomes or lysosomes into the cytoplasm. In a preferred embodiment, an oxidized carbohydrate comprises oxidized mannose units of a carbohydrate polymer substantially comprising free aldehydes. It is to be noted that a carbohydrate polymer of the present invention can include fully oxidized mannose or partially reduced mannan having aldehydes. Carbohydrates may be purified from natural sources or synthesized according to conventional procedures. Carbohydrates are available commercially from many suppliers.

Antigens may be conjugated to a carbohydrate polymer according to standard processes well known in the art of

carbohydrate chemistry for the derivatization and reaction of polysaccharides and monosaccharides. Carbohydrates may be oxidized with conventional oxidizing reagents such as a periodate, for example sodium periodate, to give a polyaldehyde which is then directly reacted with the antigen (such as repeated subunits of MUC1) where amino functional groups on the protein chain (such as the  $\epsilon$  group of lysine) react with the aldehyde groups which form Schiff's bases (See Fig. 14). Polysaccharide chains may be first activated with cyanogen bromide and the activated polysaccharide then reacted with a diamine, followed by conjugation to the antigen to form a conjugate which may optionally then be oxidized. The carbohydrate and polypeptide may be derivatized with bifunctional agents in order to cross-link the carbohydrate and polypeptide. Commonly used cross-linking agents include 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters including disuccinimidyl esters such as 3,3'-dithiobis(succinimidyl-propionate), and bifunctional maleimides such as bis-N-maleimido-1, 8-octane. Derivatizing agents such as methyl-3 [(p-azido-phenyl)dithio] propioimide yield photactivatable intermediates which are capable of forming cross-links in the

presence of light. Oxidized carbohydrates may be reacted with hydrazine derivatives of antigens to give a conjugate. Alternatively, carbohydrates may be reacted with reagents such as carbonyl diimidazole, which after oxidation gives the desired conjugate. Such methods of conjugation and oxidation have been previously discussed, for example, in PCT Application No. PCT/AU94/00789 (WO 95/18145), filed December 23, 1994, which is incorporated herein by reference in its entirety. It is to be understood that other methods of conjugation and oxidation of carbohydrates according to the present invention will be apparent to those of skill in the art and are intended to be encompassed herein.

The coupling of antigens to a carbohydrate involves converting any or all of the functional groups on the carbohydrate to reactive groups and thereafter reacting the reactive groups on the carbohydrate with reactive groups on the polypeptide. Carbohydrate polymers are replete with hydroxyl groups, and in some instances, carboxyl groups (such as in idruionate), ester groups (such as methylgalacturonate) and the like. These groups may be activated according to standard chemical procedures. For example, hydroxyl groups may be reacted with hydrogen halides, such as hydrogen iodide, hydrogen bromide and hydrogen chloride to give the reactive



halogenated polysaccharide. Hydroxy groups may be activated with phosphorous trihalides, active metals (such as sodium ethoxide, aluminium isopropoxide and potassium tert-butoxide), or esterified (with groups such as tosyl chloride or acetic acid) to form reactive groups which can be then be reacted with reactive groups on the polypeptide to form one or more bonds. Other functional groups on carbohydrates apart from hydroxyl groups may be activated to give reactive groups according to well known procedures in the art.

In one preferred embodiment of the present invention, there is provided an immunoregulatory composition comprising a population of cells enriched for mannose receptor-bearing macrophage and/or monocyte cells, and a conjugate between a human mucin polypeptide, one or more repeated or non-repeated subunits thereof, or a fragment of the repeated or non-repeated subunits, with a carbohydrate polymer comprising oxidized mannose. In particular, the immunoregulatory composition comprises a population of cells enriched for mannose receptor-bearing macrophage and/or monocyte cells that have been contacted with GM-CSF, IL-3, IL-4, TNF gamma and/or vitamin D prior to being combined with the conjugate.

Immunoregulatory compositions of the present invention can be formulated in a pharmaceutically acceptable carrier.

Examples of such carriers include water, saline, Ringer's solution, dextrose solution, Hank's solution, and other aqueous physiologically balanced salt solutions. Nonaqueous vehicles, such as fixed oils, sesame oil, ethyl oleate, or triglycerides may also be used. Other useful formulations include suspensions containing viscosity enhancing agents, such as sodium carboxymethylcellulose, sorbitol, or dextran. Excipients can also contain minor amounts of additives, such as substances that enhance isotonicity and chemical stability. Examples of buffers include phosphate buffer, bicarbonate buffer and Tris buffer, while examples of preservatives include thimerosal, m- or o-cresol, formalin and benzyl alcohol. Standard formulations can either be liquid injectables or solids which can be taken up in a suitable liquid as a suspension or solution for injection. Thus, in a non-liquid formulation, the carrier can comprise dextrose, human serum albumin, preservatives, etc., to which sterile water or saline can be added prior to administration.

Pharmaceutically acceptable carriers of the present invention can further comprise immunopotentiators, such as adjuvants or delivery vehicles. Adjuvants are typically substances that generally enhance the immune response of an animal to a specific antigen. Suitable adjuvants include

those adjuvants that can be administered to animals, in particular humans. Preferred adjuvants for use with immunoregulatory composition of the present invention include, but are not limited to, aluminum-based salts; calcium-based salts; silica; gamma interferon; IL-12 and other commercially available adjuvants.

In another aspect, an immunoregulatory composition of the present invention is administered to a patient to protect against or treat the patient for various disease states. In particular, an immunoregulatory composition of the present invention is useful for treating or preventing the growth of abnormal cells. As used herein, an abnormal cell refers to a cell displaying abnormal biological function, such as abnormal growth, development or death. Abnormal cells of the present invention, preferably include cancer cells, cells infected with an infectious agent (i.e., a pathogen) and non-cancerous cells having abnormal proliferative growth (e.g., sarcoidosis, granulomatous disease or papillomas) and with cancer cells and infected cells. Cancer cell growth includes, but is not limited to, the growth of tumors of secretory tissues, such as tumors of the breast, colon, lung, pancreas, prostate, and the like.

Some other disease states which may be protected against in this manner include, but are not limited to, type I allergies, malaria, HIV, dental caries, flu, cholera, foot and mouth disease, meningitis, Leishmania infection, whooping cough, rabies, Streptococcus infection, respiratory infection, measles, Lyme disease, tuberculosis, bacterial meningitis, shingles, rubella, hepatitis, herpes, hepatitis A, polio, venereal disease/trachoma, hepatitis B, common cold, cervical cancer, meningitis/pneumonitis, chicken pox, small pox and pneumonia/PUO.

Animals may be immunized with an immunoregulatory composition of the present invention to protect against tumor formation of secretory tissues. Alternatively, animals suffering from tumors may be immunized with the immunoregulatory composition of the present invention as part of a therapeutic regimen for tumor treatment. By way of example, to protect women from breast cancer, women may be immunized with the immunoregulatory composition of the present invention pre- or post-puberty and may receive one or more injections, preferably an initial immunization, followed by one or more booster injections separated by several months to several years. In one immunization schedule, women may be immunized with the compositions of the invention and then

receive a booster immunization at appropriate intervals. Further booster immunizations are then provided at regular intervals. The route of immunization is no different from conventional human vaccine administration. Accordingly, an immunoregulatory composition of the present invention may be administered subcutaneously, intramuscularly, orally, intravenously, and the like.

The amount of compositions of the present invention delivered to an animal is not critical or limiting. An effective amount of a composition of the invention is that which will stimulate an immune response against the antigen component. The amount of compositions delivered may vary according to the immune status of the animal (depending on whether the patient is immunosuppressed or immunostimulated), the judgement of attending physician or veterinarian whether the compound is used as a therapeutic to prevent or treat a disease state. A suitable single dose is a dose that is capable of protecting an animal from, or treating an animal with, a particular disease when administered one or more times over a suitable time period. For example, animals may receive from about  $10^5$  to about  $10^{13}$  cells in a composition of the present invention, more preferably from about  $10^6$  to about  $10^{12}$

and even more preferably from about  $10^7$  to about  $10^{11}$  in a composition of the present invention.

As described above, compositions of the present invention may be administered to animals in concert with an adjuvant, such as a cytokine or other compound that enhance an immune response. By way of example, such enhancing compounds which may be administered in concert with a composition of the present invention include one or more of GM-CSF, G-CSF, M-CSF, TNF $\alpha$  or  $\beta$ , interferon gamma or alpha, any of IL-1 through IL-18, or any other cytokine. The enhancing compound may be administered to an animal at the same time as a composition of the present invention, optionally as part of a multi-component administration form. Alternatively, the enhancing compound of and a composition of the present invention may be administered at different time intervals following administration of an immunoregulatory composition of the present invention.

In another aspect of this invention, there is provided a method for inducing an immune response against antigens which comprises administering to an animal an immunoregulatory composition of the present invention. Administration of an immunoregulatory composition of the present invention to an animal provokes a potentiated cellular response of activated T cells, in particular cytotoxic to cells reacting with the

antigen component. By way of example, an animal may be immunized against tumors which express mucins or other tumor antigenic determinants. A potential benefit of this invention arises from the fact that animals may be protected against cancer prior to tumor growth, as a composition of the present invention may provoke a cellular immune response of cytotoxic T cells which kill tumor cells expressing mucin or other antigenic determinants. This invention is particularly applicable to the immunization against tumors of secretory tissue, such as adenocarcinomas, more particularly, tumors of the breast, ovary, pancreas, colon, lung, prostate and the like.

One embodiment of the present invention includes a method for inducing an immune response in an animal, the method comprising administering to an animal an effective amount of an immunoregulatory composition comprising mannose receptor-bearing cells and a conjugate comprising an antigen and oxidized mannose. An effective amount of an immunoregulatory composition of the present invention comprises an amount capable of preventing or treating a disease as described herein.

Animals for use with the present invention include, but are not limited to, humans, companion animals and food

animals, with humans or monkeys being more preferred, and humans being most preferred..

Another embodiment of the present invention is a method to induce an immune response in an animal against cancer, the method comprising administering to an animal an effective amount of an immunoregulatory composition comprising carbohydrate receptor-bearing cells and a conjugate comprising an antigen and oxidized carbohydrate. A preferred carbohydrate for use with the present method is mannose. Any antigen disclosed herein is suitable for use with the present method. A preferred antigen comprises a mucin polypeptide.

A composition of the present invention may be administered as a part of the overall treatment for eradication of the cancer or alone. If administered as part of an overall treatment, a composition of the present invention can administered prior to, during or after another form of treatment. For example, a composition of the present invention may be administered to animals suffering from cancer either before or after surgery to remove cancerous cells. Similarly, a composition of the present invention can be administered before or after a chemotherapeutic or radiation regime following tumor excision. Preferably, a composition of the present invention is administered at a time when the



immune system of an animal is intact such that a cell mediated immune response can be induced in the animal. As such, a composition of the present invention is not preferably administered following immune ablation treatment of an animal.

5 When administering an immunoregulatory composition of the present invention to an animal having a tumor, preferably the composition is administered in or around the primary site of the tumor.

10 In a preferred embodiment, a method to induce an immune response comprises the steps of: (a) isolating a mannose receptor-bearing cell population from an animal; (b) contacting the cells with one or more biological response modifiers to produce an enhanced mannose receptor-bearing cell population; (c) combining the enhanced mannose receptor-bearing cell population with a conjugate of an antigen and oxidized mannose to produce an immunoregulatory mannose receptor-bearing cell population; and (d) administering the immunoregulatory mannose receptor-bearing cell population to an animal to induce an immune response. Preferred cytokines and vitamins for use with this embodiment are disclosed herein.

In a still further aspect, the invention relates to the use of a compound comprising a conjugate between the human

mucin polypeptide, one or more repeated subunits thereof, or a fragment of said repeated subunits and a carbohydrate polymer in the treatment of adenocarcinoma, particularly breast cancer.

5           The invention described herein is not restricted to the human mucin MUC1. The invention clearly extends to the use of other mucins expressed by cancer cells, as well as to the use of other antigens which on coupling to polysaccharides, can be used to provoke cytotoxic T cell responses against tumor  
10           cells, which compounds may be used in vaccines to prevent tumor formation, as well as for the treatment of cancer, and/or the treatment or prophylaxis of other disease states as mentioned earlier. A variety of antigens corresponding to various diseases and conditions against which the elicitation  
15           of an immune response is desirable are well known in the art, such antigens being equally included within the scope of the present invention.

20           The present invention also includes a method for delivering an antigen of the present invention to an animal that has preexisting antibodies (i.e., natural antibodies) that bind to the antigen, such method resulting in elicitation of a cellular immune response to the antigen. One of the advantages of the method of the present invention is the

ability to avoid the binding of conjugates by naturally occurring antibodies (i.e., natural antibodies) which may be capable of binding to the antigen of interest, thereby preferentially inducing an antibody response over a cellular immune response. For example, in the case of the antigen, mucin, humans have large quantities of circulating, naturally occurring antibodies that bind to the mucin peptide. The specificity of these naturally occurring antibodies is mostly derived against a galactose epitope, but these antibodies cross react with the mucin peptide. Thus, when a patient is immunized with the mannan:mucin conjugate, the antibodies presumably bind to the conjugate and prevent it from getting to the appropriate antigen presenting pathways to induce a cellular immune response (e.g., a CTL response). Therefore, the method of the present invention overcomes the preferential induction of a humoral (antibody) response by combining carbohydrate receptor-bearing cells with the antigen:carbohydrate conjugate ex vivo to avoid the circulating cross reactive antibodies upon administration of a therapeutic composition of the present invention to an animal. When introduced into a patient, a cellular immune response, and particularly a CTL and/or T1 (TH1) response, is preferentially induced by the cells presenting an antigenic

peptide of the antigen of interest. The method comprises the steps of administering to an animal a carbohydrate receptor-bearing cell that has been contacted with a conjugate comprising antigen and oxidized carbohydrate, in which the carbohydrate receptor-bearing cells are capable of presenting the antigen to a T cell in such a manner that a response is elicited from the T cell. A preferred antigen for use with the present method is mucin. A preferred carbohydrate for use with the present method is mannose.

The following examples are provided for the purposes of illustration and are not intended to limit the scope of the present invention.

#### EXAMPLES

##### Example 1

This example describes that targeting the mannose receptor *in vivo* gives rise to T<sub>1</sub> cellular immune responses.

##### A. In vitro exposure of peritoneal exudate cells to mannan-MUC1.

Peritoneal exudate cells (PEC) were prepared as follows. Mice were sacrificed, injected intraperitoneally with 10 ml phosphate buffer saline (PBS), gently massaged and peritoneal cells were collected. Adherent PECs were prepared by plating about  $2 \times 10^6$ /ml PEC in tissue culture plates and incubating at about 37°C for about 16 to about 24 hours. Non-adherent

PEC cells were dislodged with a pipette and adherent PEC cells were used in the studies described below.

5 About  $4 \times 10^6$  cells PECs from DBA/2 (H-2<sup>d</sup>) mice, after adherence for about 16 to about 24 hours, were primed with either 20 $\mu$ g/ml oxidized-mannan-MUC1 fusion protein (ox-M-FP; described in detail in Apostolopoulos et al., Proc. Natl. Acad. Sci. USA, 92:10128-10132, 1995a and Apostolopoulos et al., J. Immunol., 155:5089-5094, 1995b), reduced-mannan-MUC1 fusion protein (red-M-FP), or non-treated MUC1 fusion protein (FP; containing a peptide of 105 amino acids containing 5 VNTR repeats fused to glutathione-S-transferase, as described in detail in Apostolopoulos et al., Br. J. Cancer, 67:713-720, 1993) or mannan-ox-glutathione-S-transferase (M-GST; described in detail in Apostolopoulos et al., *ibid.*, 1993). Each group of primed cells were transferred by intraperitoneal injection into DBA/2 mice.

20 The mice were then tested for a cytotoxic T cell (CTL) response by measuring CTL precursor (CTLp) frequencies as follows. CTLp frequencies were determined using a minimum of 32 replicates of at least 6 effector cell doses by culturing the cells in U-bottomed microtiter trays, with about 2 to about  $5 \times 10^5$  DBA/2 stimulator spleen cells treated with mitomycin C at a dose of about 25  $\mu$ g/ml for about 1 to about

1.5 hours, in Dulbecco's modified Eagle's medium containing 10% fetal calf serum, 5 mM synthetic MUC1 peptide (consisting of 2 VNTR repeats; as described in Apostolopoulos et al., *ibid.*, 1995a) and about 10 U/ml recombinant human IL-2. Seven days later, each microculture was assayed for cytotoxicity by replacing 100  $\mu$ l of culture medium with 100 ml target cell suspension containing about  $10^4$   $^{51}\text{Cr}$ -labeled MUC1<sup>+</sup>P815 tumor target cells (P815 cells transfected with a cDNA encoding human MUC1; obtained as a gift from Dr. B. Acres, Transgene, Strasbourg, France). Cultures with cells having cytotoxic activity were identified by  $^{51}\text{Cr}$  release of about 3 standard deviations above the mean isotope release obtained from about  $10^4$  target cells added to responder cells cultured either alone, or with stimulator cells and recombinant IL-2 but without MUC1 synthetic peptide. A linear relationship existed between the dose of responder cells, represented on a linear scale, and the frequency of negative wells on a logarithmic scale; CTLp frequencies were determined as the inverse of responder cell dose required to generate 37% negative wells.

Referring to Fig. 1, the results indicated that the CTLp frequency obtained following a single immunization with the PEC pulsed *in vitro* with Ox-M-FP was approximately the same (1/7,000) as that obtained after 3 *in vivo* immunizations of

the cell free proteinaceous form of Ox-M-FP. A single injection of PEC pulsed *in vitro* with red-M-FP or FP generated a CTLp frequency of 1/28,000 and 1/29,600, respectively. Three intraperitoneal injections of either red-M-FP or FP gave CTLp frequencies of 1/89,000 and 1/87,500 respectively. Cells primed with M-GST gave a frequency of 1/800,000. In all cases the response was MUC1 specific because non-transfected P815 target cells were not lysed. Taken together, the results indicate that ox-M-FP, delivered either by multiple injections of the fusion protein or by a single injection of PECs pulsed *in vitro* with ox-M-FP, stimulates a higher CTL response than red-M-FP or FP alone delivered by either route. The presence of mannose on the red-M-FP provides no selective advantage (compared to non treated FP) when delivered *in vivo* as a fusion protein. Targeting of red-M-FP or FP to the mannose receptor by *in vitro* pulsing of PECs with these proteins and then using these cells for immunization, however, was more effective at eliciting CTLp (frequency approx 1/28,000 for both) than the injection of these fusion proteins (1/80,000 for both). Thus, pulsing PECs *in vitro* with Ox-M-FP (and thereby targeting to the mannose receptor) gives a better CTL response than pulsing PECs *in vitro* with red-M-FP or FP. In addition, injection of the fusion protein Ox-M-FP, but not

red-M-FP or FP, enhances the CTLp frequency. Finally, the pulsing of PECs with red-M-FP or FP *in vitro* enhances the generation of CTLp compared with the *in vivo* injection of these proteins.

5 Referring to Fig. 2, a dose response of the number of *in vitro* sensitized PECs injected, indicated that the minimum number of PECs required to enhance the CTLp frequency was  $10^4$  cells.  $10^4$  cells gave a CTLp frequency (1/10,200), not substantially different than that obtained with 400 times more cells ( $4 \times 10^6$  cells; CTLp frequency 1/4,000). Thus, at  
10 numbers greater than  $10^4$  transferred PECs, the CTLp frequency was not dose-dependent on the number of transferred cells and was similar in the range of  $10^4 - 4 \times 10^6$  cells. When  $10^3$  cells were transferred, the CTLp frequency fell to 1/44,000.

15 B. Mice immunized with *in vitro* pulsed PECs were protected from a tumor challenge.

To examine the ability of the sensitized PECs to elicit protective responses against tumor challenge, groups of 5  
20 DBA/2 mice were injected once with either ox-M-FP, or PECs pulsed with ox-M-FP, or with non-pulsed PECs, and then challenged with  $5 \times 10^6$  MUC1<sup>+</sup>P815 cells. Referring to Fig. 3, the results indicated that there was no detectable tumor growth in any of the five mice immunized with PECs primed with  
25 oxidized-M-FP. Conversely, three of five mice immunized once



with oxidized-M-FP developed tumors and five of five mice immunized once with non-pulsed PECs developed tumors.

Thus, PECs derived from the peritoneal cavity of mice and cultured *in vitro* with oxidized-M-FP can, after adoptive transfer, efficiently process and present a MUC1 antigen, leading to the generation of high frequency of CTLs, and protection against a subsequent tumor challenge.

C. Binding studies of reduced and oxidized M-FP.

Experiments were performed to analyze the binding of the different mannan forms to different types of tissues, cell lines, cells and receptors. Table 1 summarizes the results of such binding studies.

**Table 1.** Binding studies of mannan, oxidized mannan or reduced mannan (FITC labeled)

Cell	Mannan	Oxidized Mannan	Reduced Mannan
<b>Cell lines</b>			
5 3T3 (fibroblast)	-	-	-
P815 (mastocytoma)	-	-	-
NS1 (B cell line)	-	-	-
Sultan (B cell line)	-	-	-
EL-4 (T cell line)	-	-	-
10 RMA (T cell line)	-	-	-
E3 (T cell line)	-	-	-
CEM (T cell line)	-	-	-
MM200 (melanoma)	-	-	-
COS (kidney cell line)	-	-	-
15 BHK (kidney cell line)	-	-	-
J774 (macrophage)	+	+	+
D2SC/1 (DC)	±	-	±
<b>Carbohydrate inhibition studies</b> (+ denotes binding of the FITC-mannan; whereas – denotes inhibition)			
20 J774 (macrophage)	+	-	+
N-acetylgalactosamine	-	+	-
galactose	+	+	+
glucose	+	+	+
25 mannan	-	-	-
mannose	-	-	-
L-fucose	-	-	-
D-fucose	+	+	+
<b>Tissues</b>			
30 Spleen	+	+	++
Lymph node	+	+	+
Thymus	-	-	-
<b>Cells</b>			
35 Macrophages (F4/80)	+	+	+
Dendritic (33D1)	-	-	-
<b>Receptors</b>			
40 Mannose (COS)	++	+	++
Mannose (Western)	++	++	++
Scavenger (ScR)	±	±	±
using CHO transfectant cell lines, ScR GKO mice and inhibitors for ScR			
Sialoadhesin	-	-	-
45 CR3	-	-	-

- = negative, ± = weak, + = strong, ++ = very strong

# 1. Cell Lines

Either reduced or oxidized mannan conjugated with fluorescein isothiocyanate (FITC available from Sigma, St. Louis, MO; described in detail in Apostolopoulos et al., *ibid.*, 1995a) were mixed with various types of cells using methods generally described in Apostolopoulos et al., *ibid.*, 1995a. Neither FITC-conjugated reduced, or oxidized, mannan bound to the following cell lines: 3T3 (fibroblast) cells, P815 (mastocytoma) cells, NS1 and Sultan (B cell lines) cells, EL-4 cells, RMA cells, E3 cells and CEM (T cell lines) cells, MM200 (melanoma) cells, COS cells and BHK (kidney cell lines) cells. Both FITC-conjugated reduced-, and FITC-conjugated oxidized-, mannan bound to J774 (macrophage cell line, obtained as a gift from Dr. P. Ricciardi-Castagnoli, Milan, Italy) cells. Binding to the dendritic cell line, D2SC/1, was negative with oxidized-mannan-FITC and very weak with reduced-mannan-FITC (Table 1).

Inhibition studies were performed using carbohydrates to inhibit the binding of oxidized or reduced mannose conjugated with FITC; to J774 cells. Binding of oxidized-mannan-FITC to J774 cells was inhibited by mannan, D-mannose, L-fucose and N-acetylglucosamine whereas binding of reduced-mannan-FITC was inhibited by mannan, D-mannose, L-fucose and N-

acetylgalactosamine; other sugars (glucose, D-fucose and galactose) did not inhibit (Table 1). The ability of these sugars to inhibit the binding of the FITC conjugated mannan forms is indicative of their binding to the mannose receptor.

5           2.   Tissues

Reduced and oxidized mannan-FITC were injected into mice intraperitoneally and after 1 hour organs were fixed in 4% paraformaldehyde and analyzed by confocal microscopy using standard methods. Both the oxidized and reduced material was found in the liver where the staining was around the sinusoids which is rich in Kupffer cells; in the spleen where the staining was around the white pulp and in the red pulp where the staining was with the marginal zone macrophages. The results are summarized in Table 1.

10           3.   Receptors

COS cells transfected with a nucleic acid molecule encoding the mannose receptor were mixed with either red-M-FP or ox-M-FP under conditions that allowed for binding of the M-FP to mannose receptor. M-FP binding to mannose receptor was confirmed by resolving M-FP complexed to receptor by SDS-PAGE gel, blotting the protein separated on the gel and resolving bands by Western blot using an antibody that binds specifically to the mannose receptor. The results indicated

that both red-M-FP and ox-M-FP also bound to the mannose receptor.

#### 4. Characterization of PEC

The cell surface markers used to define macrophages and dendritic cells were F4/80, 33D1 and NLDC-145. Macrophages were classified as F4/80<sup>+</sup>33D1<sup>-</sup> and dendritic cells were classified as F4/80<sup>-</sup>33D1<sup>+</sup>. Adherent PECs were analyzed by flow cytometry as follows. Adherent PECs were stained using standard techniques with either F4/80 antibody (a rat anti-mouse monoclonal antibody that detects macrophages but not dendritic cells; described in Austyn et al., Eur. J. Immunol., 11:805-812, 1981 and Nussenzweig et al., J. Exp. Med., 154:168-179, 1981); 33D1 antibody (a rat anti-mouse monoclonal antibody that reacts with mouse dendritic cells but not macrophages; described in Steinman, et al., J. Exp. Med., 157:613-627, 1983); and NLDC-145 antibody (a rat anti-mouse monoclonal antibody that detects the DEC-205 molecule on dendritic cells, which is absent from macrophages; described in Swiggard, et al., Cell. Immunol., 165:302-11, 1995 and provided as a gift by Dr. Derek Hart, Christchurch Hospital, Christchurch, New Zealand). The stained cells were resolved by flow cytometry using standard methods. For serological studies; about 100  $\mu$ l of each antibody was added to about 2 x

10<sup>5</sup> PEC cells and incubated for about 1 hour at about 4°C. The cells were washed three times with about .5 ml PBS. About 100 µl of a 1:50 dilution of FITC-conjugated sheep (Fab')<sub>2</sub> anti-mouse immunoglobulin (available from Silenus, Australia) was added to each sample and incubated for about 45 minutes at about 4°C. The cells were washed again and then analyzed by flow cytometry, using a FACScan flow cytometer.

The results are summarized in Table 2 and indicate that about 75% of the adherent PECs were F4/80<sup>+</sup>; about 30% were NLDC-145<sup>+</sup> and about 33% were 33D1<sup>+</sup>. About 5% of the adherent PECs were double positive (F4/80<sup>+</sup> 33D1<sup>+</sup>).

**Table 2.** Phenotype of cells by flow cytometry

PEC cells		% positive			
Monoclonal antibodies to:					
F4/80		75			
NLDC-145		30			
33D1		33			
PBS		7			
% positive staining with antibodies to:					
Cells	F4/80	33D1	NLDC-145	PBS	
F4/80 <sup>+</sup> /33D1 <sup>-</sup>	80	17	12	14	
F4/80 <sup>+</sup> /33D1 <sup>+</sup>	3	85	3	3	
% positive staining with FITC conjugated mannan forms					
	Mannan	OxMannan	RedMannan	PBS	
F4/80 <sup>+</sup> /33D1 <sup>-</sup>	46	70	52	7	
F4/80 <sup>+</sup> /33D1 <sup>+</sup>	3	3	5	5	

20

A population of adherent PECs were then separated using Dynabeads™ into two populations. One population (macrophage enriched) was comprised of about 80% F4/80<sup>+</sup>, about 13% 33D1<sup>+</sup>, about 14% F4/80<sup>-</sup>33D1<sup>-</sup>. The second population (dendritic cell enriched) was about 3% F4/80<sup>+</sup>, about 85% 33D1<sup>+</sup> and about 3% F4/80<sup>-</sup>33D1<sup>-</sup> (see Table 2). The method used to derive these two populations is as follows: Dynabeads (M-450) that were coated with antibody to sheep anti rat IgG, were mixed with

25

either of the two rat monoclonal antibodies, F4/80 or 33D1,

30

for 3 hours at 4°C. These treated Dynabeads were then added separately to 10<sup>7</sup> PECs and mixed for 30 minutes at 4°C. The cells which had bound to the antibody coated Dynabeads were removed with a magnet and the cells which had not bound Dynabeads were collected for further study. A sample of these cells which had not bound Dynabeads was tested by flow cytometry for the ability to bind the F4/80 or the 33D1 antibody. The rest of the cells which had not bound Dynabeads were then incubated with ox-M-FP for 16 to 24 hours and adoptively transferred into the peritoneum of syngeneic mice using the method described above in section A (see next example).

The macrophage (33D1<sup>-</sup>) and dendritic cell (F4/80<sup>-</sup>) enriched populations described immediately above were further characterized for expression of the mannose receptor by flow cytometry using mannan-FITC, oxidized mannan-FITC or reduced mannan-FITC. About 100 µl of each FITC conjugate was added to about 2 x 10<sup>5</sup> macrophage or dendritic cell enriched populations and incubated for about 1 hour at about 4°C. The cells were washed three times with about .5 ml PBS. The cells were analyzed by flow cytometry, using a FACScan flow cytometer. Referring to Table 2, about 46% of the cells in the F4/80<sup>+</sup>33D1<sup>-</sup> population were stained with mannan-FITC and



58% of the cells in this population bound both mannan-FITC and F4/80 antibody. The F4/80<sup>-</sup>33D1<sup>+</sup> population did not bind mannan-FITC (5% or less, which was the number of positive cells in the sample which received PBS). About 52% of the F4/80<sup>+</sup> population stained with reduced-M-FITC (65% of the cells in this population bound both reduced-mannan-FITC and F4/80 antibody). Again the 33D1<sup>+</sup> cell population did not bind reduced-mannan-FITC. About 70% of F4/80<sup>+</sup> population stained with oxidized-M-FITC and 58% of the cells in this population bound both oxidized-mannan-FITC and F4/80 antibody. Again the 33D1<sup>+</sup> cell population did not bind oxidized-mannan-FITC. Thus, both forms of mannan (reduced and oxidized) bind to macrophages but not to dendritic cells, with the oxidized material binding best.

5. Determination of the preferential role of macrophages and dendritic cells in the PEC population

PEC were separated into two populations containing either 80% F4/80<sup>+</sup>33D1<sup>-</sup> macrophage enriched cells and 85% F4/80<sup>-</sup>33D1<sup>+</sup> dendritic cells using either F4/80 or 33D1 antibodies and Dynabeads as described above in section D. The separated macrophage and dendritic cell populations were cultured separately *in vitro* with about 20  $\mu$ g of M-FP for about 16 to about 24 hours. An unfractionated PEC population was cultured similarly. The cell populations were then injected

intraperitoneally into separate mice and the MUC1 specific CTLp frequencies were determined using the methods generally described above in section A.

**Table 3.** CTLp in mice immunized with adoptively transferred cells

Cells	Number of cells transferred	CTLp frequency*
PEC	$1 \times 10^6$	1/11,000
F4/80 <sup>+</sup> (Mac)	$6 \times 10^5$	1/15,000
33D1 <sup>+</sup> (DC)	$2 \times 10^5$	1/64,000
F4/80 <sup>+</sup> (Mac)	$2 \times 10^5$	1/13,000
33D1 <sup>+</sup> (DC)	$2 \times 10^5$	1/65,000
J774 (Mac)	$1 \times 10^6$	1/33,000
D2SC/1 (DC)	$1 \times 10^6$	1/130,000

\* Average of two individual mice

Referring to Table 3, the results indicated that injection of  $10^6$  *in vitro* pulsed PEC produced a CTLp frequency of 1/11,000. Similarly,  $6 \times 10^5$  pulsed macrophages produced a CTLp frequency of 1/15,000 whereas  $2 \times 10^5$  dendritic cells produced a CTLp frequency of 1/64,000. Thus, the mannose receptor positive, F4/80<sup>+</sup> macrophages were primarily responsible for the increase in CTLp frequency. The dendritic cells, which are mannose receptor negative, were less effective in enhancing the CTLp frequency.

In the above experiment the number of injected macrophages ( $6 \times 10^5$ ) was different from the number of injected dendritic cells ( $2 \times 10^5$ ). A comparison was

subsequently made using the same dose ( $2 \times 10^5$ ) of each of the cell types. Macrophage and dendritic cell populations were prepared as described immediately above and injected into mice. About  $2 \times 10^5$  macrophages and about  $2 \times 10^5$  dendritic cells were injected into separate mice and the MUC1 specific CTLp frequency determined. Injection of the macrophages produced a CTLp frequency of 1/13,000 whereas injection of the dendritic cells produced a CTLp frequency of 1/65,000 (see Table 3). Thus, the macrophages are the major effector cells in generating high CTLp frequency when mice receive cells pulsed *in vitro* with ox-M-FP.

The role of the dendritic cells in MUC1 antigen presentation was also determined by immunizing BALB/c mice once with about  $10^6$  J774 cells pulsed *in vitro* with ox-M-FP for 16 to 24 hours. The J774 cells produced a CTLp frequency of 1/33,000 (see Table 3). BALB/c mice were also immunized once with D2SC/1 cells (a dendritic cell line) pulsed with ox-M-FP for 16 to 24 hours. Injection of D2SC/1 cells produced a CTLp frequency of 1/130,000 (see Table 3). These results demonstrate that macrophages pulsed with ox-M-FP are more effective than dendritic cells pulsed with ox-M-FP at increasing the CTLp frequency.

6. Effect of GM-CSF on the immune responses generated with PEC pulsed with ox-M-FP

PECs were isolated from mice, adhered to plastic, pulsed  
5 with oxidized-M-FP and incubated with either GM-CSF (about 10  
ng/ml) or with gamma interferon for about 3 hours, *in vitro*.  
Some cells were incubated with ox-M-FP for about 3 hours in  
the absence of cytokine. Referring to Fig. 4, the cells were  
then transferred to separate naive mice. Transfer of the GM-  
10 CSF treated cells produced a CTLp frequency of 1/2,500.  
Transfer of the untreated cells produced a CTLp frequency of  
1/7,000. Conversely, transfer of cells treated with gamma  
interferon produced a CTLp of 1/9,000.

In another study, PECs were isolated from mice, adhered  
15 to plastic and pulsed with ox-M-FP. The pulsed cells were  
then injected into either GM-CSF o/o mice (mice lacking GM-CSF  
produced by homologous recombination; obtained from Dr. Ashley  
Dunn), G-CSF o/o mice (mice lacking G-CSF produced by  
homologous recombination; obtained from Dr. Ashley Dunn) or  
20 wild type mice. This process was repeated for a total of  
three injections for each mouse. Referring to Fig. 5, the  
results indicated that transfer of PECs isolated from the wild  
type mice produced a CTLp frequencies of 1/8,000 in wild type  
mice, 1/16,000 in G-CSF o/o mice and 1/32,000 in GM-CSF o/o  
25 mice. The GM-CSF o/o mice were further immunized with M-FP

and were also given GM-CSF. The CTLp frequency present in these mice increased to 1/16,000. Thus, the CTLp response to PECs pulsed in vitro with ox-M-FP is partially GM-CSF dependent and can be augmented by GM-CSF.

5 In another study, wild type mice were injected intraperitoneally with  $1\mu\text{g}$  of recombinant GM-CSF per day for either 2, 3, 4, 5, or 6 days. PECs were isolated from these mice, counted and stained using F4/80 or 33D1 antibodies and standard methods. Stained cells were then detected by flow  
10 cytometry using standard methods. About  $10^6$  resident PEC cells/mouse was isolated after one day (1 injection). About  $9.6 \times 10^6$  macrophages (F4/80<sup>+</sup> cells) were obtained after 2 days (2 injections), about  $1.2 \times 10^7$  macrophages after 3 days (3 injections), and about  $2 \times 10^7$  macrophages after 4 to 6 days  
15 (4 to 6 injections). Four days of GM-CSF injections were optimal in isolating the most number of macrophages. A group of mice was then injected with  $1\mu\text{g}$  of recombinant GM-CSF per day for 4 days. On the fifth day, a single injection of ox-M-FP was then administered to these mice as well as to a group  
20 of mice that had not been treated with GM-CSF. Referring to Fig. 6, mice that were treated with GM-CSF and then received one injection of ox-M-FP had a CTLp frequency of 1/9,900. Mice that did not receive GM-CSF, but were given one injection

of ox-M-FP had a CTLp frequency of 1/45,000. Thus the CTLp response to injection of the Ox-M-FP protein can be enhanced by the administration of GM-CSF.

7. Transfer of semi-allogeneic macrophages in mice

5        Macrophages isolated from DBA/2 mice were either pulsed, or not pulsed, with ox-M-FP as described above. The two cell populations were then injected separately into either DBA/2, C57BL/6 or (DBA/2 x C57BL/6)F1 mice. Referring to Fig. 7, injection of the pulsed macrophages into DBA/2 mice produced  
10       a CTLp frequency of 1/8,000; injection of the pulsed macrophages into C57BL/6 mice produced a CTLp frequency of 1/220,000; and injection of the pulsed macrophages into (DBA/2 x C57BL/6)F1 mice produced a CTLp frequency of 1/10,000. Mice injected with non pulsed macrophages had a CTLp frequency of  
15       <1/10<sup>6</sup>. The same methods described immediately above were repeated, except that the PECs were isolated from (DBA/2 x C57BL/6)F1 mice and, following pulsing with ox-M-FP, were injected into either C57BL/6 or DBA/2 mice. Transfer of ox-M-FP pulsed PECs from (DBA/2 x C57BL/6)F1 mice into either  
20       C57BL/6 or DBA/2 mice produced a high CTLp frequency. Thus the immune response can be transferred semi-allogeneically (i.e. where one haplotype is shared).

Taken together, the results described in sections A through G indicated that culturing macrophage cells with ox-M-FP, and adoptively transferring the cells to syngeneic mice, induces a specific CTL response to MUC1. In addition, one immunization of macrophages pulsed with oxidized-M-FP led to protection from MUC1<sup>+</sup> tumors. The single immunization with macrophages pulsed *in vitro* with ox-M-FP provides an increase in CTLp equivalent to that conferred by three immunizations with the ox-M-FP fusion protein. Thus, targeting the mannose receptor by *in vitro* pulsing with ox-M-FP, gives rise to T<sub>1</sub> cellular immune responses.

#### Example 2

This example describes the comparison between reducing agents sodium borohydride and sodium cyanoborohydride.

Ox-M-FP was prepared as described above in Example 1. Three different samples were prepared as follows. A portion of ox-M-FP was combined with 0.5 mg/milliliter (ml) of sodium borohydride to reduce Schiff's bases and aldehydes. Another portion of ox-M-FP was combined with 0.5 mg/ml of sodium cyanoborohydride to reduce predominantly Schiff bases only. A third portion remained untreated. Five  $\mu$ g of each of the three samples were injected into separate mice. Cytotoxic T

cell frequencies (CTLp) were determined using the methods generally described above in Example 1.

The results indicated that the CTLp frequency induced by ox-M-FP treated with sodium cyanoborohydride was 1/10,300.

5 The CTLp frequency induced by ox-M-FP treated with sodium borohydride was 1/79,500. The CTLp frequency induced by the untreated ox-M-FP was 1/14,575. Taken together, the results indicated that aldehyde groups on ox-M-FP are important for CTL induction.

10 Example 3

This example describes the effect of culturing peripheral blood mononuclear cells with GM-CSF, IL-3 and vitamin D.

Peripheral blood mononuclear cells (PBMC) were isolated from a normal human donor using standard methods. The freshly  
15 isolated PBMC were cultured in wells of a standard 6-well tissue culture plate in serum-free AIM-V medium at a density of  $10 \times 10^6$  cells per 2 ml of medium per well, for 2 hours. Following the incubation step, non-adherent cells were removed from the wells. About 2 ml of fresh serum-free AIM-V medium  
20 containing 1 nanogram per ml (ng/ml) GM-CSF, 10 ng/ml of IL-3, 10 ng/ml IL-4, 50 ng/ml TNF alpha and 50 nM vitamin D was added to each well. The cells were incubated for 2, 4 and 7 days.



At each pre-determined time point, cells were collected and analyzed for the expression of mannose receptor as well as cell surface marker that identify monocytes, macrophages and dendritic cells. Expression was determined by FACS analysis using methods generally described above in Example 1. The following reagents were used in the FACS analysis: fluorescein-conjugated (FITC) oxidized mannan (ox-M-FITC; described in Example 1); phycoerythrin (PE) conjugated CD11b, PE conjugated CD11c, PE conjugated CD14, FITC conjugated CD68, FITC conjugated CD80, PE conjugated CD86 and PE conjugated CD54.

The results of the FACS analysis are described below in Table 4.

**Table 4.** Percent of monocyte, macrophage and dendritic cells after activation with cytokine\*.

Antibody	Day 0	Day 2	Day 4	Day 7
CD54-PE	40	99	99	99
CD11b-PE	28	97	87	93
CD11C-PE	22	98	93	96
CD14-PE	20	92	50	70
CD68-FITC	14	59	27	66
CD80-FITC	17	61	33	44
CD86-PE	21	98	92	89
Ox-M-FITC	41	69	44	25

\*The cells were gated on the large non-lymphocytic population.

The highest number of mannose receptor positive cells were generated after 2 days of culture Day 4 of the incubation. This correlates well with an increase in CD54, CD80 and CD86 bearing cells which represent cellular activation markers. Further more were either monocytes or macrophages, but not dendritic cells.

#### Example 4

This example describes the binding of antibodies to MUC1 and Gala(1,3)Gal antibodies are cross-reactive with Gala(1,3)Gal and MUC1, respectively.

Several mice were analyzed for the presence of antibodies that bind specifically to Gala(1,3)Gal or MUC1. The sera were obtained from either normal mice, mice in which the Gal gene had been deleted by homologous recombination (gal o/o mice), and mice immunized intraperitoneally, three times with about 5  $\mu$ g of MUC1 peptide. The presence of antibodies that bind to MUC1 in these sera was determined by their ability to bind to cell lines which either did (BT-20 cells or RMA-MUC1 cells) or did not (ME272 or RMA cells) express MUC1. The binding of antibodies to these cells was determined by FACS analysis using methods generally described in Example 1.

Referring to Fig. 8, serum from the normal mice did not bind to any of the cell lines. The antiserum raised against

MUC1 contained antibodies that bound to BT-20 cells (panel A of Fig. 8) and RMA-MUC1 cells (panel C of Fig. 8), but did not bind to ME272 (panel B of Fig. 8) or RMA cells (panel D of Fig. 8).

5           The BT-20 cells and ME272 cells do not express Gala(1,3)Gal, whereas the RMA-MUC1 and RMA cells express Gala(1,3)Gal. Serum from the gal o/o mice contain natural antibodies to galactose as demonstrated by the reactivity with BT-20 cells (MUC<sup>-</sup>gal<sup>+</sup> cells; panel A of Fig. 8) and RMA-MUC1  
10 cells (MUC<sup>+</sup>gal<sup>+</sup>) cells (panel C of Fig. 8), weak on RMA cells (MUC<sup>-</sup>gal<sup>+</sup>; panel D of Fig. 8) and ME272 cells (MUC<sup>-</sup>gal<sup>-</sup>) were negative. The serum from the gal o/o mice contained antibodies that bound stronger to the RMA-MUC1 cells, which differ from the RMA cells only by the expression of MUC1.

15           Taken together, the results indicated that expression of MUC1 by RMA cells and expression of MUC1 on BT-20 cells confers reactivity with the anti-gal antibodies present in the gal o/o mice. Thus, naturally-occurring antibodies in gal o/o mice reacted with MUC1 and antibodies raised against MUC1  
20 reacted with Gala(1,3)Gal.

#### Example 5

This example describes that animals which express Gala(1,3)Gal do not have naturally-occurring antibodies to

Gala(1,3)Gal and do not produce antibodies that bind to MUC1 when immunized with oxidized mannan-MUC1.

Multiple immunizations of animals with about 5  $\mu$ g ox-M-FP (described in Example 1) were performed at weekly intervals and were given at the following sites: intraperitoneally in mice; intramuscularly in rabbits and chickens; and into humans and monkeys. Sera obtained from the immunized animals were examined for the presence of antibodies to MUC1 by enzyme-linked immunoassay (ELISA) using the following method. A standard microtiter plate was coated with a 10  $\mu$ g/ml solution of MUC1 peptide (described above in Example 1) in phosphate buffered saline (PBS), for about 16 hours at 4°C. The unbound peptide was removed from the plate. The plate was washed using standard methods. The plate was then coated with a 2% w/v solution of bovine serum albumin (BSA) for about 2 hours at about 4°C. The was removed from the plate and the plate washed using standard methods. About 50  $\mu$ l of various dilutions of mouse, rabbit, chicken, human and monkey sera were added to separate wells on the coated plate and incubated for about 2 hours at room temperature. The plate was then washed to remove unbound antibodies. The presence of antibodies bound to the plate from each species of animal was detected using secondary antibodies including sheep anti-mouse

antibody to detect mice antibodies; anti-rabbit antibody to detect rabbit antibodies; anti-chicken antibody to detect chicken antibodies; anti-human antibody to detect human antibodies; and anti-monkey antibody to detect monkey antibodies. These antibodies were added to the plate and the plate was incubated for about 1 hour at room temperature. The presence of secondary antibody bound to the plate was detected using about 50  $\mu$ l of 0.03% 2,2'-azino-di(3)-ethylbenzthiazoline sulfonate (available from Amersham, U.K.), .02% hydrogen peroxide in a about .1 M citrate buffer, at about pH 4. The reaction was developed for about 10 to about 15 minutes at room temperature and then the absorbance read at 405 nm using an ELISA reader.

Referring Fig. 9, immunization of normal C57BL/6 mice with ox-M-FP did not elicit any detectable production of antibodies that bound to MUC1 when immobilized on the microtiter plate. Conversely, immunization of gal o/o mice with ox-M-FP resulted in the production of high titers, about  $10^{-4}$  dilution, of antibodies that bound to MUC1. The naturally-occurring antibodies to gal present in the gal o/o mice react with intact MUC1 or MUC1 fusion protein in solution, but do not react with the synthetic peptide of MUC1 immobilized on the microtiter plate. This was indicated that

the lack of reactivity of the pre-immune sera from gal o/o mice with immobilized MUC1 peptide (Fig. 9). In addition, several other animals which are negative for Gala(1,3)Gal demonstrated high titers for antibodies that bound to ox-M-FP (see Table 5). Rabbits, which are negative for Gala(1,3)Gal, did not produce antibodies that bound to MUC1. Thus, the animals that were positive for Gala(1,3)Gal (i.e., mice and rabbits), and did not have pre-existing antibodies that bound to galactose, did not produce anti-MUC1 antibodies following immunization with ox-M-FP. In contrast, animals that were negative for galactose (i.e., humans, monkeys, chickens and gal o/o mice), produced anti-MUC1 antibodies in response to immunization with ox-M-FP.

**Table 5.** Immune responses generated in different species immunized with mannan-MUC1

	Species	Immune Responses		
		Antibody <sup>a</sup>	CTL <sup>b</sup>	CTLp <sup>c</sup>
a) Gal status of species				
Gala(1,3)Gal <sup>+</sup> /anti-Gal Ab <sup>-</sup>	mice (normal)	-	+	++
	mice (MUC1 Tg <sup>d</sup> )	-	+	+
	rabbits	-	Nt <sup>e</sup>	NT
Gala(1,3)Gal <sup>-</sup> /anti-Gal Ab <sup>+</sup>	humans	++	± <sup>f</sup>	NT
	monkeys	++	-	+ <sup>g</sup>
	chickens	++	-	NT
	mice (gal o/o)	++	NT	±
b) Immune responses in normal mice immunized with mannan-MUC1 in the presence of serum (NMS or gal o/o serum)				
NMS <sup>h</sup>		-	NT	++
Gal o/o serum		++	NT	±
c) Immune responses in mice immunized with macrophages pulsed with mannan-MUC1 in the absence or presence of NMS or gal o/o serum				
normal mice		-	NT	++
+ NMS		-	NT	++
+ Gal o/o serum		++	NT	±
Gal o/o mice		-	NT	++

a: - = titre < 1/50, ++ = titre > 1:500

b: - = negative, ± = weak, + = strong

c: ± = < 1/50,000, + = between 1/15,000 and 1/50,000, ++ = > 1/15,000

d: Tg = transgenic; e: NT = not tested; f: 2/10 patients generated a weak CTL response<sup>g</sup>; g: 1/4 monkeys generated a weak CTLp response (Submitted).

h: NMS, normal mouse serum

### Example 6

This example describes that animals that are positive for Gala(1,3)Gal generate CTLp, rather than antibody, in response to immunization with mannan-MUC1.

Normal mice and gal o/o mice were injected with ox-M-FP and the resulting CTLp frequencies measured using methods generally described in Example 1. Referring to Fig. 11, either one or three injections of normal mice with ox-M-FP

produced CTLp frequencies of 1/70,000 and 1/10,000, respectively. Similar injections into gal o/o mice resulted in CTLp frequencies of 1/200,000 (one injection) and 1/60,000 (three injections). Normal and gal o/o mice were also  
5 injected in a similar manner with a control peptide derived from ovalbumin. The difference in CTLp frequency in normal and gal o/o mice that was observed using ox-M-FP, was not observed using an ovalbumin epitope. Referring to Fig. 12, three immunizations of normal or gal o/o mice with mannan  
10 conjugated ovalbumin peptide gave CTLp frequencies of 1/10,000 and 1/12,000, respectively. Therefore, the reduced CTLp response in gal o/o mice was unique to MUC1 and gal o/o mice were capable of mounting CTLp responses to other antigens. The results indicated that CTLp frequency response to ox-M-FP  
15 immunization was greater in normal mice compared with gal o/o mice. These results are opposite to the antibody production results described above in Example 5.

In a separate study, monkeys were immunized with ox-M-FP in a similar manner as the mice described immediately above.  
20 Referring to Table 5, monkeys immunized with ox-M-FP produced an antibody response, but not a CTLp response. This result is similar to that obtained using the gal o/o mice.



Thus, in species in which CTLp can be measured, there is a correlation between the absence of pre-existing antibodies to galactose and the enhancement of CTLp responses by immunization with ox-M-FP.

5     Example 7

      This example describes that antibodies to galactose reduce the appearance of CTLp when mixed with ox-M-FP prior to immunization of an animal.

      Normal mice received either a single injection or three  
10    injections of either ox-M-FP or ox-M-FP mixed with gal o/o  
      sera which contain anti-galactose antibodies. CTLp  
      frequencies were obtained for the immunized mice using the  
      methods generally described in Example 1. Referring to Fig.  
      11, mice that received a single injection gave a CTLp  
15    frequency of 1/62,000 when immunized with ox-M-FP and  
      1/275,000 when immunized with ox-M-FP mixed with gal o/o sera.  
      Similarly, the CTLp frequencies for mice injected three times  
      was 1/8,000 for ox-M-FP and 1/59,000 for ox-M-FP mixed with  
      gal o/o sera. Thus, the addition of anti-galactose antibodies  
20    to ox-M-FP limited the generation of CTLp frequencies in  
      normal mice to the level observed in gal o/o mice. In  
      addition, injection of normal mice with ox-M-FP mixed with gal

o/o serum led to significant antibody production (see Table 5).

#### Example 8

5 This example describes the immunization of normal and gal o/o mice with macrophage cells pulsed *in vitro* with ox-M-FP and the generation of CTLp, but not antibody, in such mice.

10 Macrophage cells were obtained from C57BL/6 mice using the methods generally described in Example 1. The macrophage cells were pulsed overnight using either ox-M-FP or ox-M-FP mixed with gal o/o serum, using the methods generally described in Example 1. Normal and gal o/o mice were immunized with the pulsed macrophage cells using the methods generally described in Example 1.

15 Referring to Fig. 13, immunization of gal o/o mice with the pulsed macrophages did elicit CTLp to a level essentially equivalent to normal mice (1/11,500 and 1/8,000, respectively), but did not elicit a detectable antibody response (see Fig. 10). Immunization of mice with macrophages pulsed with ox-M-FP mixed with gal o/o serum did not elicit a strong CTLp response.

20 While various embodiments of the present invention have been described in detail, it is apparent that modifications and adaptations of those embodiments will occur to those skilled in the art. It is to be expressly understood,

however, that such modifications and adaptations are within the scope of the present invention, as set forth in the following claims:

What is claimed is:

1. An immunoregulatory composition comprising isolated mannose receptor-bearing cells and a conjugate comprising an antigen and mannose selected from the group consisting of fully oxidized mannose and partially reduced mannose having aldehydes.

2. The composition of Claim 1, wherein said mannose is partially reduced mannose having aldehydes.

3. The composition of Claim 1, wherein said mannose receptor-bearing cells are derived from a cell population selected from the group consisting of peripheral blood leukocytes, bone marrow, stem cells, tumor cells, stromal cells, peritoneal cells, spleen, lung and lymph node cells.

4. The composition of Claim 1, wherein said mannose receptor-bearing cells comprise cells that are enriched for cells selected from the group consisting of macrophage cells and dendritic cells.

5. The composition of Claim 1, wherein said mannose receptor-bearing cells comprise cells that express molecules selected from the group consisting of mannose receptor, CD11b, CD14, CD68, CD80 and CD86.

6. The composition of Claim 1, wherein said mannose receptor-bearing cells are combined with said conjugate *in vitro*.

7. The composition of Claim 1, wherein said mannose receptor-bearing cells are combined with said conjugate *ex vivo*.

8. The composition of Claim 1, wherein said mannose receptor-bearing cells comprise cells that have been contacted with one or more biological response modifiers.

9. The composition of Claim 8, wherein said biological response modifiers are capable of inducing mannose receptors on a cell capable of expressing said mannose receptors.

10. The composition of Claim 8, wherein said biological response modifiers are selected from the group consisting of a cytokine and a vitamin.

11. The composition of Claim 8, wherein said biological response modifiers are selected from the group consisting of GM-CSF, interleukin-3, interleukin-4, vitamin D, GM-CSF, M-CSF, Flt-3 ligand and TNF alpha.

12. The composition of Claim 1, wherein said antigen is selected from the group consisting of nm23, p53, Her2/neu, MUC1, BRCA1, BRCA2, MAGE antigen, CEA, Erb2, pollen, hepatitis C virus (HIV) core, E1, E2 and NS2 proteins,

5 Plasmodium falciparum circumsporozoite protein, HIV-gp120/160  
 envelope glycoprotein, streptococcus surface protein Ag,  
 influenza nucleoprotein, hemagglutinin-neuraminidase surface  
 infection, TcpA pilin subunit, VP1 protein, LMCV  
 nucleoprotein, Leishmania major surface glycoprotein (gp63),  
 10 Bordetella pertussis surface protein, rabies virus G protein,  
 Streptococcus M protein, respiratory syncytial virus (RSV) F  
 or G proteins, Epstein Barr virus (EBV) gp340 or nucleocapsid  
 protein, hemagglutinin, Borrelia burgdorferi outer surface protein  
 (Osp) A, Mycobacterium tuberculosis 38kDa lipoprotein or Ag85,  
 15 Neisseria meningitidis class 1 outer protein, Varicella zoster  
 virus IE62 and gpI, Rubella virus capsid protein, Hepatitis B  
 virus pre S1 ag, Herpes simplex virus type I glycoprotein G or  
 gp D or CP27, Murray valley encephalitis virus E glycoprotein,  
 Hepatitis A virus VP1, polio virus capsid protein VP1, VP2 and  
 20 VP3, chlamydia trachomatis surface protein, Hepatitis B virus  
 envelope Ag pre S2, Human rhinovirus (HRV) capsid,  
 papillomavirus peptides from oncogene E6 and E7, Listeria  
 surface protein, Varicella virus envelope protein, Vaccinia  
 virus envelope protein, Brucella surface protein, a  
 25 combination of one or more of said antigens, an amino acid  
 subunit of said antigens comprising five or more amino acids  
 in length or combinations of one or more of said subunits.

13. The composition of Claim 1, wherein said antigen is a mucin polypeptide, one or more repeated subunits thereof, or a fragment of said repeated subunits.

14. The composition of Claim 13, wherein said mucin is human mucin.

15. The composition of Claim 13, wherein said antigen comprises two to eighty copies of the repeated subunits of human mucin.

16. The composition of Claim 13, wherein said one or more repeated subunits of said antigen comprise part of a fusion polypeptide.

17. The composition of Claim 1, wherein said mannose is selected from the group consisting of mannose and a conformational and configurational isomer of mannose.

18. The composition of Claim 1, wherein said mannose comprises a carbohydrate polymer comprised of two or more carbohydrate units.

19. The composition of Claim 1, wherein said composition further comprises a pharmaceutically acceptable carrier.

20. A composition comprising an immunoregulatory mannose receptor-bearing cell population, said population can be derived by culturing mannose receptor-bearing cells under conditions effective to produce said immunoregulatory mannose receptor-bearing cell population, said conditions comprising an antigen delivery medium.

21. The composition of Claim 20, wherein said antigen delivery medium comprises a conjugate comprising an antigen and mannose selected from the group consisting of fully oxidized mannose and partially reduced mannose having aldehydes.

22. The composition of Claim 20, wherein said mannose is partially reduced mannose having aldehydes.

23. The composition of Claim 21, wherein said mannose comprises a carbohydrate polymer comprised of two or more carbohydrate units.

24. The composition of Claim 20, wherein said mannose receptor-bearing cell population has been incubated in the presence of one or more biological response modifiers prior to said step of culturing.

25. The composition of Claim 24, wherein said biological response modifier selected from the group consisting of GM-



CSF, interleukin-3, interleukin-4, vitamin D, GM-CSF, M-CSF, Flt-3 ligand and TNF alpha.

26. The composition of Claim 20, wherein said step of culturing is performed *in vitro*.

27. An immunoregulatory mannose receptor-bearing cell population, wherein said immunoregulatory mannose receptor-bearing cell population can be derived by a method comprising:

5 a) culturing mannose receptor-bearing cells in vitro with one or more biological response modifiers to produce an enhanced mannose receptor-bearing cell population; and

10 b) incubating said enhanced mannose receptor-bearing cell population with a conjugate comprising an antigen and mannose selected from the group consisting of fully oxidized mannose and partially reduced mannose having aldehydes, to obtain said immunoregulatory mannose receptor-bearing cell population.

28. The population of Claim 27, wherein said step of culturing is performed from about 1 hour to about 6 hours.

29. The population of Claim 27, wherein said step of culturing is performed for about 3 hours.

30. The population of Claim 27, wherein said step of incubating is performed from about 10 hour to about 30 hours.

31. The population of Claim 27, wherein said step of incubating is performed from about 16 hour to about 24 hours.

32. The population of Claim 27, wherein said mannose receptor-bearing cells comprise cells that are enriched for

cells selected from the group consisting of macrophage cells and dendritic cells.

33. The population of Claim 27, wherein said biological response modifier is capable of increasing the number of mannose receptors on cells.

34. The population of Claim 27, wherein said biological response modifier is selected from the group consisting of GM-CSF, interleukin-3, interleukin-4, vitamin D, GM-CSF, M-CSF, Flt-3 ligand and TNF alpha.

35. The population of Claim 27, wherein said mannose is partially reduced mannose having aldehydes.

36. The population of Claim 27, wherein said antigen comprises mucin.

37. The population of Claim 27, wherein said antigen comprises human mucin.

38. A mucin antigen delivery vehicle, comprising an isolated mannose receptor-bearing cell and a conjugate comprising mucin antigen and a carbohydrate polymer comprising mannose selected from the group consisting of fully oxidized mannose and partially reduced mannose having aldehydes.
- 5

39. A method for obtaining a population comprising immunoregulatory mannose receptor-bearing cells, said method comprising culturing a population of cells enriched for mannose receptor-bearing cells under conditions effective to obtain immunoregulatory mannose receptor-bearing cells, said conditions comprising an antigen delivery medium.

40. The method of Claim 39, wherein said step of culturing is performed *in vitro*.

41. The method of Claim 39, wherein said step of culturing is performed from about 10 hour to about 30 hours.

42. The method of Claim 39, wherein said step of culturing is performed from about 16 hour to about 24 hours.

43. The method of Claim 39, wherein said antigen delivery medium comprises a conjugate comprising an antigen and mannose selected from the group consisting of fully oxidized mannose and partially reduced mannose having aldehydes.

44. The method of Claim 43, wherein said antigen comprises mucin.

45. The method of Claim 43, wherein said antigen comprises human mucin.

46. The method of Claim 43, wherein said mannose is partially reduced mannose having aldehydes.

47. The method of Claim 43, wherein said mannose comprises a carbohydrate polymer comprised of two or more carbohydrate units.

48. The method of Claim 43, wherein said method further comprises incubating said population of cells enriched for mannose receptor-bearing cells in the presence of one or more biological response modifier prior to said step of culturing.

49. The method of Claim 48, wherein said biological response modifier is selected from the group consisting of GM-CSF, interleukin-3, interleukin-4, vitamin D, GM-CSF, M-CSF, Flt-3 ligand and TNF alpha.

50. The method of Claim 48, wherein said step of incubating is performed *in vitro*.

51. The method of Claim 48, wherein said step of incubating is performed for about 3 hours.

52. A method to induce an immune response comprising administering to a recipient animal an effective amount of an immunoregulatory composition comprising mannose receptor-bearing cells and a conjugate comprising an antigen mannose selected from the group consisting of fully oxidized mannose and partially reduced mannose having aldehydes.

53. The method of Claim 52, wherein said mannose is partially reduced mannose having aldehydes.

54. The method of Claim 52, wherein said immune response comprises a cell mediated immune response.

55. The method of Claim 52, wherein said mannose receptor-bearing cells are obtained from an animal that is MHC matched to said recipient animal.

56. The method of Claim 52, wherein said mannose receptor-bearing cells are obtained from an animal selected from the group consisting of said recipient animal, an unrelated donor of said recipient animal and a relative of said recipient animal.

57. The method of Claim 52, wherein said method comprises:

a) contacting said mannose receptor-bearing cells with one or more biological response modifiers to produce an enhanced mannose receptor-bearing cell population;

b) culturing said enhanced mannose receptor-bearing cell population with said conjugate to obtain said immunoregulatory mannose receptor-bearing cell population; and

10 c) administering said immunoregulatory mannose receptor-bearing cell population to said animal to induce an immune response.

58. The method of Claim 57, wherein said step of contacting is performed *in vitro*.



59. A method to induce an immune response to mucin, comprising contacting an isolated mannose receptor-bearing cell with a conjugate comprising mucin and mannose selected from the group consisting of fully oxidized mannose and partially reduced mannose having aldehydes, and administering said contacted cell to an animal.

60. A method for delivering mucin to an animal having natural antibodies therein that bind to mucin, to preferentially induce a cellular immune response to mucin, comprising administering to an animal a mannose receptor-bearing cell that has been contacted with a conjugate comprising mucin and mannose selected from the group consisting of fully oxidized mannose and partially reduced mannose having aldehydes, wherein said mannose receptor-bearing cell is capable of presenting said mucin to a T cell in such a manner that a response is elicited from said T cell.

61. A therapeutic compound, comprising an antigen conjugated to a carbohydrate polymer comprising partially reduced carbohydrate having aldehyde groups.

5 62. The therapeutic compound of Claim 61, wherein said carbohydrate polymer comprises partially reduced mannose having aldehyde groups.

63. The therapeutic compound of Claim 62, wherein said mannose is selected from the group consisting of mannose and a conformational and configurational isomer of mannose.

64. The therapeutic compound of Claim 62, wherein said mannose comprises a carbohydrate polymer comprised of two or more carbohydrate units.

65. The therapeutic compound of Claim 61, wherein said antigen is selected from the group consisting of nm23, p53, Her2/neu, MUC1, BRCA1, BRCA2, MAGE antigen, CEA, Erb2, pollen, hepatitis C virus (HIV) core, E1, E2 and NS2 proteins, Plasmodium falciparum circumsporozoite protein, HIV-gp120/160 envelope glycoprotein, streptococcus surface protein Ag, influenza nucleoprotein, hemagglutinin-neuraminidase surface infection, TcpA pilin subunit, VP1 protein, LMCV nucleoprotein, Leishmania major surface glycoprotein (gp63), Bordetella pertussis surface protein, rabies virus G protein, Streptococcus M protein, respiratory syncytial virus (RSV) F

or G proteins, Epstein Barr virus (EBV) gp340 or nucleocapsid protein 3A, hemagglutinin, *Borrelia burgdorferi* outer surface protein (Osp) A, *Mycobacterium tuberculosis* 38kDa lipoprotein or Ag85, *Neisseria meningitidis* class 1 outer protein, Varicella zoster virus IE62 and gpI, Rubella virus capsid protein, Hepatitis B virus pre S1 ag, Herpes simplex virus type I glycoprotein G or gp D or CP27, Murray valley encephalitis virus E glycoprotein, Hepatitis A virus VP1, polio virus capsid protein VP1, VP2 and VP3, *Chlamydia trachomatis* surface protein, Hepatitis B virus envelope Ag pre S2, Human rhinovirus (HRV) capsid, papillomavirus peptides from oncogene E6 and E7, *Listeria* surface protein, Varicella virus envelope protein, Vaccinia virus envelope protein, *Brucella* surface protein, a combination of one or more of said antigens, an amino acid subunit of said antigens comprising five or more amino acids in length or combinations of one or more of said subunits.

66. The therapeutic compound of Claim 61, wherein said antigen is a mucin polypeptide, one or more repeated subunits thereof, or a fragment of said repeated subunits.

67. The therapeutic compound of Claim 66, wherein said mucin is human mucin.

68. The therapeutic compound of Claim 66, wherein said antigen comprises two to eighty copies of the repeated subunits of human mucin.

69. The therapeutic compound of Claim 66, wherein said one or more repeated subunits of said antigen comprise part of a fusion polypeptide.

**SECRET**

5

Mice immunised with:




FIG. 1

09163089.092998  
856260.6809750

Dose of transferred  
sensitised macrophages




FIG. 2

09163089-099993






FIG. 3

Mice immunised  
macrophages  
sensitised with:




FIG. 4

Ox-M-FP immunized mice




FIG. 5




FIG. 6

Mouse strain cells  
transferred to:




FIG. 7

09163089.092995




FIG. 8




FIG. 9




FIG. 10



Mice immunised  
with: Ox-M-FP

normal mice x3

gal o/o mice x3

normal mice x1

gal o/o mice x1

Normal mice  
immunised with:

Ox-M-FP+NMS x3

Ox-M-FP+Gal o/o serum x3

Ox-M-FP x3

Ox-M-FP+Gal o/o serum x1

Ox-M-FP x1





FIG. 11

09163089-092598

Mice immunised  
with: SIINFEKL

normal mice

gal o/o mice



CTLp Frequency (1/)

FIG. 12

Mice immunised with:  
Macrophages+M-FP

normal mice

gal o/o mice

Mice immunised with:  
Macrophages+M-FP-  
in the presence of:

normal mouse serum

gal o/o serum




FIG. 13

09163089.09998

09163089 090998




FIG. 14

# SEQUENCE LISTING

<110> McKenzie, Ian F.C.

Apostolopoulos, Vasso

Pietersz, Geoffrey Allan

<120> COMPOSITIONS FOR IMMUNOTHERAPY AND USES THEREOF

<130> 4102-1

<140> Not Yet Assigned

<141> 1998-09-29

<150> 08/340,711

<151> 1994-11-16

<150> 60/060,594

<151> 1997-09-29

<150> 08/833,807

<151> 1997-04-09

<160> 9

<170> PatentIn Ver. 2.0

<210> 1

<211> 20

<212> PRT

<213> Homo sapiens

<400> 1

Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala

1

5

10

15

His Gly Val Thr

20

<210> 2

<211> 23

<212> PRT

<213> Homo sapiens

<400> 2

Pro Thr Thr Thr Pro Ile Ser Thr Thr Thr Met Val Thr Pro Thr Pro

1

5

10

15

Thr Pro Thr Gly Thr Gln Thr  
20

<210> 3  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 3  
His Ser Thr Pro Ser Phe Thr Ser Ser Ile Thr Thr Thr Glu Thr Thr  
1 5 10 15

Ser

<210> 4  
<211> 16  
<212> PRT  
<213> Homo sapiens

<400> 4  
Thr Ser Ser Ala Ser Thr Gly His Ala Thr Pro Leu Pro Val Thr Asp  
1 5 10 15

<210> 5  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 5  
Pro Thr Thr Ser Thr Thr Ser Ala  
1 5

<210> 6  
<211> 23  
<212> PRT  
<213> Homo sapiens

<400> 6  
Thr Thr Ala Ala Pro Pro Thr Pro Pro Ala Thr Thr Pro Ala Pro Pro  
1 5 10 15

Ser Ser Ser Ala Pro Pro Glu  
20

<210> 7  
<211> 5  
<212> PRT  
<213> Homo sapiens

<400> 7  
Ala Pro Asp Thr Arg  
1 5

<210> 8  
<211> 9  
<212> PRT  
<213> Homo sapiens


<400> 8  
Ala Pro Asp Thr Arg Pro Ala Pro Gly  
1 5

<210> 9  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 9  
Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro  
1 5 10

00163089.09998  
366260.6809360

United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



Application deficiencies were found during scanning:

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

No Declaration

☐ Scanned copy is best available.

09163089-09999  
8809T60